BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu AX, Kang Y, Yen C, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, Rau K, Motomura K, Ohno I, Merle P, Daniele B, Shin DB, Gerken G, Borg C, Hiriart J, Okusaka T, Morimoto M, Hsu Y, Abada PB, Kudo M. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 2019;20:282-96. [DOI: 10.1016/s1470-2045(18)30937-9] [Cited by in Crossref: 473] [Cited by in F6Publishing: 294] [Article Influence: 157.7] [Reference Citation Analysis]
Number Citing Articles
1 Shao YY, Li YS, Hsu HW, Lin H, Wang HY, Wo RR, Cheng AL, Hsu CH. Potent Activity of Composite Cyclin Dependent Kinase Inhibition against Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1433. [PMID: 31561409 DOI: 10.3390/cancers11101433] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
2 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Tran NH, Foster NR, Mahipal A, Byrne T, Hubbard J, Silva A, Mody K, Alberts S, Borad MJ. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance). Invest New Drugs 2021;39:1072-80. [PMID: 33646489 DOI: 10.1007/s10637-021-01090-w] [Reference Citation Analysis]
4 Harding JJ, Do RK, Yaqubie A, Cleverly A, Zhao Y, Gueorguieva I, Lahn M, Benhadji KA, Kelley RK, Abou-Alfa GK. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma. Cancer Med 2021;10:3059-67. [PMID: 33811482 DOI: 10.1002/cam4.3880] [Reference Citation Analysis]
5 Odagiri N, Hai H, Thuy LTT, Dong MP, Suoh M, Kotani K, Hagihara A, Uchida-Kobayashi S, Tamori A, Enomoto M, Kawada N. Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. Cancers (Basel) 2020;12:E2045. [PMID: 32722224 DOI: 10.3390/cancers12082045] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Martini G, Ciardiello D, Paragliola F, Nacca V, Santaniello W, Urraro F, Stanzione M, Niosi M, Dallio M, Federico A, Selvaggi F, Della Corte CM, Napolitano S, Ciardiello F, Martinelli E. How Immunotherapy Has Changed the Continuum of Care in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4719. [PMID: 34572944 DOI: 10.3390/cancers13184719] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Wang CI, Chu PM, Chen YL, Lin YH, Chen CY. Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. Int J Mol Sci 2021;22:13627. [PMID: 34948424 DOI: 10.3390/ijms222413627] [Reference Citation Analysis]
8 Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu Z, Li Q, Luo M, Liang R, Ye J. Molecular targeted and immune checkpoint therapy for advanced hepatocellular carcinoma. J Exp Clin Cancer Res. 2019;38:447. [PMID: 31684985 DOI: 10.1186/s13046-019-1412-8] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 15.7] [Reference Citation Analysis]
9 Pan YX, Sun XQ, Hu ZL, Xie W, Nie KX, Fang AP, Zhang YY, Fu YZ, Chen JB, Wang JC, Wang X, Zhang YJ, Hu DD, Chen MS. Prognostic Values of Alpha-Fetoprotein and Des-Gamma-Carboxyprothrombin in Hepatocellular Carcinoma in China: An Analysis of 4792 Patients. J Hepatocell Carcinoma 2021;8:657-70. [PMID: 34235104 DOI: 10.2147/JHC.S316223] [Reference Citation Analysis]
10 Chen J, A Gingold J. Dysregulated PJA1-TGF-β signaling in cancer stem cell-associated liver cancers. Oncoscience 2020;7:88-95. [PMID: 33457451 DOI: 10.18632/oncoscience.522] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Qiu H, Ke S, Cai G, Wu Y, Wang J, Shi W, Chen J, Peng J, Yu B, Chen Y. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Med 2022. [PMID: 35633045 DOI: 10.1002/cam4.4900] [Reference Citation Analysis]
12 Ikeda A, Aoki K, Kawamura M, Yamaguchi D, Kokuryu H. Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma. Intern Med 2021;60:403-7. [PMID: 33518611 DOI: 10.2169/internalmedicine.5552-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Mehta N, Parikh ND, Kelley RK, Hameed B, Singal AG. Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic. Clin Gastroenterol Hepatol 2021;19:1520-30. [PMID: 32652308 DOI: 10.1016/j.cgh.2020.06.072] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
14 Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. JPM 2022;12:738. [DOI: 10.3390/jpm12050738] [Reference Citation Analysis]
15 Simón Serrano S, Tavecchio M, Grönberg A, Sime W, Jemaà M, Moss S, Gregory MA, Gallay P, Elmér E, Hansson MJ, Massoumi R. Novel Cyclophilin Inhibitor Decreases Cell Proliferation and Tumor Growth in Models of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3041. [PMID: 34207224 DOI: 10.3390/cancers13123041] [Reference Citation Analysis]
16 Pinter M, Scheiner B, Peck-Radosavljevic M. Immunotherapy for advanced hepatocellular carcinoma: a focus on special subgroups. Gut 2021;70:204-14. [PMID: 32747413 DOI: 10.1136/gutjnl-2020-321702] [Cited by in Crossref: 62] [Cited by in F6Publishing: 52] [Article Influence: 62.0] [Reference Citation Analysis]
17 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
18 Effing SMA, Gyawali B. Assessing the risk-benefit profile of ramucirumab in patients with advanced solid tumors: A meta-analysis of randomized controlled trials. EClinicalMedicine 2020;25:100458. [PMID: 32954236 DOI: 10.1016/j.eclinm.2020.100458] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kudo M. Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: present and future perspective. Hepatobiliary Surg Nutr 2021;10:241-5. [PMID: 33898567 DOI: 10.21037/hbsn-20-707] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Celsa C, Giuffrida P, Giacchetto CM, Stornello C, Rancatore G, Grova M, Ricciardi MR, Rizzo S, Cammà C, Cabibbo G. Hepatotoxicity of systemic therapies for unresectable hepatocellular carcinoma. Liver Cancer International 2021;2:82-95. [DOI: 10.1002/lci2.38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
22 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
23 Merle P. The New Immuno-Oncology-Based Therapies and Their Perspectives in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:E238. [PMID: 33440630 DOI: 10.3390/cancers13020238] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
24 Ochi H, Tani J, Tomonari T, Taniguchi T, Koizumi Y, Hirose A, Ogawa C, Hiraoka A, Morishita A, Moriya A, Hirooka M, Deguchi A, Symple Study Group. Sequential therapy including regorafenib for unresectable hepatocellular carcinoma: Effect of early relative changes in hepatic functional reserve after regorafenib administration on prognosis. Hepatol Res 2021;51:1219-28. [PMID: 34534398 DOI: 10.1111/hepr.13713] [Reference Citation Analysis]
25 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms – Kurzversion 2.00 – Juni 2021, AWMF-Registernummer: 032-053OL. Z Gastroenterol 2022;60:81-107. [PMID: 35042249 DOI: 10.1055/a-1589-7520] [Reference Citation Analysis]
26 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
27 Dipasquale A, Marinello A, Santoro A. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario. J Hepatocell Carcinoma 2021;8:241-51. [PMID: 33884259 DOI: 10.2147/JHC.S270532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Zhang C, Yang M. The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3740. [PMID: 34359642 DOI: 10.3390/cancers13153740] [Reference Citation Analysis]
29 Gu X, Zhang S, Zhang T. Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity. Cells 2021;10:869. [PMID: 33921219 DOI: 10.3390/cells10040869] [Reference Citation Analysis]
30 Alqahtani SA, Colombo M. Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib-time has come for a better approach. Ann Transl Med 2020;8:1255. [PMID: 33178787 DOI: 10.21037/atm-2020-79] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Lee HW, Cho KJ, Park JY. Current Status and Future Direction of Immunotherapy in Hepatocellular Carcinoma: What Do the Data Suggest? Immune Netw 2020;20:e11. [PMID: 32158599 DOI: 10.4110/in.2020.20.e11] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
32 Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q, Zhang H, Tong Z, Liu L, Zheng Y, Zhao P, Fang W. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma. Theranostics 2021;11:3489-501. [PMID: 33537099 DOI: 10.7150/thno.54648] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 11.0] [Reference Citation Analysis]
33 Jordan AC, Wu J. Immunotherapy in hepatocellular carcinoma: Combination strategies. World J Meta-Anal 2020; 8(3): 190-209 [DOI: 10.13105/wjma.v8.i3.190] [Reference Citation Analysis]
34 Finkelmeier F, Scheiner B, Leyh C, Best J, Fründt TW, Czauderna C, Beutel A, Bettinger D, Weiß J, Meischl T, Kütting F, Waldschmidt DT, Radu P, Schultheiß M, Peiffer KH, Ettrich TJ, Weinmann A, Wege H, Venerito M, Dufour JF, Lange CM, Pinter M, Waidmann O. Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort. Liver Cancer 2021;10:360-9. [PMID: 34414123 DOI: 10.1159/000515490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
35 Sangro B, Melero I, Wadhawan S, Finn RS, Abou-Alfa GK, Cheng AL, Yau T, Furuse J, Park JW, Boyd Z, Tang HT, Shen Y, Tschaika M, Neely J, El-Khoueiry A. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. J Hepatol. 2020;73:1460-1469. [PMID: 32710922 DOI: 10.1016/j.jhep.2020.07.026] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 16.0] [Reference Citation Analysis]
36 Schultheiß M, Bengsch B, Thimme R. [Hepatocellular Carcinoma]. Dtsch Med Wochenschr 2021;146:1411-20. [PMID: 34670284 DOI: 10.1055/a-1226-3047] [Reference Citation Analysis]
37 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
38 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Grimaudo S, Matranga D, Attanasio M, Bruzzi P, Craxì A, Cammà C. Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis. Cancers (Basel) 2020;12:E2132. [PMID: 32752060 DOI: 10.3390/cancers12082132] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
39 Akce M, El-rayes BF, Bekaii-saab TS. Frontline therapy for advanced hepatocellular carcinoma: an update. Therap Adv Gastroenterol 2022;15:175628482210861. [DOI: 10.1177/17562848221086126] [Reference Citation Analysis]
40 Yokoo H, Takahashi H, Hagiwara M, Iwata H, Imai K, Saito Y, Matsuno N, Furukawa H. Successful hepatic resection for recurrent hepatocellular carcinoma after lenvatinib treatment: A case report. World J Hepatol 2020; 12(12): 1349-1357 [PMID: 33442460 DOI: 10.4254/wjh.v12.i12.1349] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M. Immunological Microenvironment Predicts the Survival of the Patients with Hepatocellular Carcinoma Treated with Anti-PD-1 Antibody. Liver Cancer 2021;10:380-93. [PMID: 34414125 DOI: 10.1159/000516899] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
42 Kudo M. Surveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update. Liver Cancer 2021;10:167-80. [PMID: 34239807 DOI: 10.1159/000516491] [Reference Citation Analysis]
43 Mauro E, Forner A. Barcelona Clinic Liver Cancer 2022 update: Linking prognosis prediction and evidence-based treatment recommendation with multidisciplinary clinical decision-making. Liver Int 2022;42:488-91. [PMID: 35194931 DOI: 10.1111/liv.15180] [Reference Citation Analysis]
44 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR; AASLD Panel of Experts on Trial Design in HCC. Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference. Hepatology 2021;73 Suppl 1:158-91. [PMID: 32430997 DOI: 10.1002/hep.31327] [Cited by in Crossref: 66] [Cited by in F6Publishing: 46] [Article Influence: 66.0] [Reference Citation Analysis]
45 Tomonari T, Sato Y, Tanaka H, Tanaka T, Fujino Y, Mitsui Y, Hirao A, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Kagiwada H, Kitazawa M, Fukui K, Horimoto K, Takayama T. Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. Oncotarget 2020;11:2531-42. [PMID: 32655838 DOI: 10.18632/oncotarget.27640] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
46 Aitcheson G, Pillai A, Dahman B, John BV. Recent Advances in Systemic Therapies for Advanced Hepatocellular Carcinoma. Curr Hepatol Rep 2021;:1-11. [PMID: 33552839 DOI: 10.1007/s11901-021-00560-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Barcena-Varela M, Lujambio A. The Endless Sources of Hepatocellular Carcinoma Heterogeneity. Cancers (Basel) 2021;13:2621. [PMID: 34073538 DOI: 10.3390/cancers13112621] [Reference Citation Analysis]
48 Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52:1898-1907. [PMID: 33268834 DOI: 10.1038/s12276-020-00527-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
49 Kawabe N, Hashimoto S, Nakano T, Nakaoka K, Fukui A, Yoshioka K. Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma. JGH Open 2021;5:705-11. [PMID: 34124389 DOI: 10.1002/jgh3.12573] [Reference Citation Analysis]
50 Müller L, Stoehr F, Mähringer-Kunz A, Hahn F, Weinmann A, Kloeckner R. Current Strategies to Identify Patients That Will Benefit from TACE Treatment and Future Directions a Practical Step-by-Step Guide. J Hepatocell Carcinoma 2021;8:403-19. [PMID: 34012930 DOI: 10.2147/JHC.S285735] [Reference Citation Analysis]
51 Scheiner B, Pinter M. Reply to: "Prognostic prediction for patients with hepatocellular carcinoma receiving immunotherapy: Are we there yet?". J Hepatol 2022;76:988-9. [PMID: 34979133 DOI: 10.1016/j.jhep.2021.12.025] [Reference Citation Analysis]
52 Delos Santos S, Udayakumar S, Nguyen A, Ko YJ, Berry S, Doherty M, Chan KKW. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma. Curr Oncol 2020;27:300-6. [PMID: 33380861 DOI: 10.3747/co.27.6583] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Borgia M, Dal Bo M, Toffoli G. Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4387. [PMID: 34503196 DOI: 10.3390/cancers13174387] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
54 Li ZJ, Dai HQ, Huang XW, Feng J, Deng JH, Wang ZX, Yang XM, Liu YJ, Wu Y, Chen PH, Shi H, Wang JG, Zhou J, Lu GD. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin 2021;42:301-10. [PMID: 32699265 DOI: 10.1038/s41401-020-0478-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
55 Choucair K, Kamran S, Saeed A. Clinical Evaluation of Ramucirumab for the Treatment of Hepatocellular Carcinoma (HCC): Place in Therapy. Onco Targets Ther 2021;14:5521-32. [PMID: 35002257 DOI: 10.2147/OTT.S268309] [Reference Citation Analysis]
56 Jácome AA, Castro ACG, Vasconcelos JPS, Silva MHCR, Lessa MAO, Moraes ED, Andrade AC, Lima FMT, Farias JPF, Gil RA, Prolla G, Garicochea B. Efficacy and Safety Associated With Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma: A Meta-analysis. JAMA Netw Open 2021;4:e2136128. [PMID: 34870682 DOI: 10.1001/jamanetworkopen.2021.36128] [Reference Citation Analysis]
57 Tada T, Kumada T, Hiraoka A, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib. Sci Rep 2021;11:14474. [PMID: 34262065 DOI: 10.1038/s41598-021-93794-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
58 von Felden J, Craig AJ, Garcia-Lezana T, Labgaa I, Haber PK, D'Avola D, Asgharpour A, Dieterich D, Bonaccorso A, Torres-Martin M, Sia D, Sung MW, Tabrizian P, Schwartz M, Llovet JM, Villanueva A. Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma. Oncogene. 2021;40:140-151. [PMID: 33097857 DOI: 10.1038/s41388-020-01519-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
59 Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V, Rapaccini GL, Di Marco M, Caturelli E, Magalotti D, Sacco R, Celsa C, Campani C, Mega A, Guarino M, Gasbarrini A, Svegliati-baroni G, Foschi FG, Olivani A, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Brunetto MR, Trevisani F, Farinati F. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol 2022;12:822507. [DOI: 10.3389/fonc.2022.822507] [Reference Citation Analysis]
60 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 3.3] [Reference Citation Analysis]
61 Singh P, Toom S, Avula A, Kumar V, Rahma OE. The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020;7:11-17. [PMID: 32104669 DOI: 10.2147/jhc.s187121] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
62 Oh H, Lee JH. Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis. Ann Transl Med 2020;8:1530. [PMID: 33313275 DOI: 10.21037/atm-20-3526] [Reference Citation Analysis]
63 van Doorn DJ, Takkenberg RB, Klümpen HJ. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview. Pharmaceuticals (Basel) 2020;14:3. [PMID: 33374927 DOI: 10.3390/ph14010003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Personeni N, Pressiani T, Rimassa L. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date. J Hepatocell Carcinoma 2019;6:31-9. [PMID: 30775342 DOI: 10.2147/JHC.S168953] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 7.7] [Reference Citation Analysis]
65 Chuma M, Yokoo H, Hiraoka A, Ueda K, Yokoyama T, Tsuji K, Shimada N, Uojima H, Kobayashi S, Hattori N, Okubo T, Atsukawa M, Ishikawa T, Takaguchi K, Tsutsui A, Toyoda H, Tada T, Saito Y, Hirose S, Tanaka T, Takeda K, Otani M, Sekikawa Z, Watanabe T, Hidaka H, Morimoto M, Numata K, Kagawa T, Sakamoto M, Kumada T, Maeda S. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment. Current Oncology 2022;29:3259-71. [DOI: 10.3390/curroncol29050266] [Reference Citation Analysis]
66 Takeda K, Tsurumaru Y, Yamamoto Y, Araki K, Kogure Y, Mori K, Nakagawa K, Shimizu T, Matsuda G, Niino H, Sekido H, Kobayashi S, Morimoto M, Kunisaki C, Endo I. Treatment of hepatocellular carcinoma with hepatic vein tumor thrombosis protruding into the inferior vena cava by conversion surgery following chemotherapy with regorafenib: a case report. Clin J Gastroenterol 2020;13:428-33. [PMID: 31970661 DOI: 10.1007/s12328-019-01077-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
67 Matsumoto K, Tamiya A, Matsuda Y, Taniguchi Y, Atagi S, Kawachi H, Tamiya M, Tanizaki S, Uchida J, Ueno K, Yanase T, Suzuki H, Hirashima T. Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study. Transl Lung Cancer Res 2021;10:1642-52. [PMID: 34012781 DOI: 10.21037/tlcr-20-1263] [Reference Citation Analysis]
68 Fulgenzi CAM, D'Alessio A, Ogunbiyi O, Demirtas CO, Gennari A, Cortellini A, Sharma R, Pinato DJ. Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? Expert Opin Investig Drugs 2022;:1-11. [PMID: 35507361 DOI: 10.1080/13543784.2022.2072726] [Reference Citation Analysis]
69 Foerster F, Galle PR. Comparison of the current international guidelines on the management of HCC. J Hep Reports. 2019;1:114-119. [PMID: 32039359 DOI: 10.1016/j.jhepr.2019.04.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
70 Kalathil SG, Wang K, Hutson A, Iyer R, Thanavala Y. Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients. Oncoimmunology 2020;9:1824863. [PMID: 33101775 DOI: 10.1080/2162402X.2020.1824863] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
71 Kudo M. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma. Int J Clin Oncol. [DOI: 10.1007/s10147-022-02166-0] [Reference Citation Analysis]
72 Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M. ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. Ther Adv Med Oncol 2021;13:17588359211039928. [PMID: 34616489 DOI: 10.1177/17588359211039928] [Reference Citation Analysis]
73 Vène E, Jarnouen K, Ribault C, Vlach M, Verres Y, Bourgeois M, Lepareur N, Cammas-marion S, Loyer P. Circumsporozoite Protein of Plasmodium berghei- and George Baker Virus A-Derived Peptides Trigger Efficient Cell Internalization of Bioconjugates and Functionalized Poly(ethylene glycol)-b-poly(benzyl malate)-Based Nanoparticles in Human Hepatoma Cells. Pharmaceutics 2022;14:804. [DOI: 10.3390/pharmaceutics14040804] [Reference Citation Analysis]
74 Cabibbo G, Aghemo A, Lai Q, Masarone M, Montagnese S, Ponziani FR. Optimizing systemic therapy for advanced hepatocellular carcinoma: the key role of liver function. Digestive and Liver Disease 2022. [DOI: 10.1016/j.dld.2022.01.122] [Reference Citation Analysis]
75 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
76 Qing X, Xu W, Zong J, Du X, Peng H, Zhang Y. Emerging treatment modalities for systemic therapy in hepatocellular carcinoma. Biomark Res 2021;9:64. [PMID: 34419152 DOI: 10.1186/s40364-021-00319-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Olejarz W, Kubiak-Tomaszewska G, Chrzanowska A, Lorenc T. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers. Int J Mol Sci 2020;21:E5840. [PMID: 32823989 DOI: 10.3390/ijms21165840] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
78 Personeni N, Pressiani T, Bozzarelli S, Rimassa L. Targeted agents for second-line treatment of advanced hepatocellular carcinoma. World J Gastrointest Oncol 2019; 11(10): 788-803 [PMID: 31662820 DOI: 10.4251/wjgo.v11.i10.788] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
79 Golkowski M, Lau HT, Chan M, Kenerson H, Vidadala VN, Shoemaker A, Maly DJ, Yeung RS, Gujral TS, Ong SE. Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Syst 2020;11:196-207.e7. [PMID: 32755597 DOI: 10.1016/j.cels.2020.07.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Reig M, Forner A, Rimola J, Ferrer-Fábrega J, Burrel M, Garcia-Criado A, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2021:S0168-8278(21)02223-6. [PMID: 34801630 DOI: 10.1016/j.jhep.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Li H, Qin S, Liu Y, Chen Z, Ren Z, Xiong J, Meng Z, Zhang X, Wang L, Zhang X, Zou J. Camrelizumab Combined with FOLFOX4 Regimen as First-Line Therapy for Advanced Hepatocellular Carcinomas: A Sub-Cohort of a Multicenter Phase Ib/II Study. Drug Des Devel Ther 2021;15:1873-82. [PMID: 33976538 DOI: 10.2147/DDDT.S304857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Wang L, Yan K, He X, Zhu H, Song J, Chen S, Cai S, Zhao Y, Wang L. LRP1B or TP53 mutations are associated with higher tumor mutational burden and worse survival in hepatocellular carcinoma. J Cancer 2021;12:217-23. [PMID: 33391418 DOI: 10.7150/jca.48983] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
83 Harding JJ, Kelley RK, Tan B, Capanu M, Do GK, Shia J, Chou JF, Ferrer CS, Boussayoud C, Muenkel K, Yarmohammadi H, El Dika I, Khalil DN, Ruiz C, Rodriguez-Lee M, Kuhn P, Wilton J, Iyer R, Abou-Alfa GK. Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma. Oncologist 2020;25:e1825-36. [PMID: 32548867 DOI: 10.1634/theoncologist.2020-0521] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
84 Hatanaka T, Kakizaki S, Nagashima T, Namikawa M, Ueno T, Tojima H, Takizawa D, Naganuma A, Arai H, Sato K, Harimoto N, Shirabe K, Uraoka T. Liver Function Changes in Patients with Hepatocellular Carcinoma Treated with Lenvatinib: Predictive Factors of Progression to Child-Pugh Class B, the Formation of Ascites and the Candidates for the Post-Progression Treatment. Cancers (Basel) 2020;12:E2906. [PMID: 33050527 DOI: 10.3390/cancers12102906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
85 Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol 2021;12:731527. [PMID: 34804015 DOI: 10.3389/fimmu.2021.731527] [Reference Citation Analysis]
86 Deng S, Solinas A, Calvisi DF. Cabozantinib for HCC Treatment, From Clinical Back to Experimental Models. Front Oncol 2021;11:756672. [PMID: 34722310 DOI: 10.3389/fonc.2021.756672] [Reference Citation Analysis]
87 Zhu XD, Li KS, Sun HC. Adjuvant therapies after curative treatments for hepatocellular carcinoma: Current status and prospects. Genes Dis 2020;7:359-69. [PMID: 32884990 DOI: 10.1016/j.gendis.2020.02.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
88 Ayoub WS, Jones PD, Yang JD, Martin P. Emerging drugs for the treatment of hepatocellular carcinoma. Expert Opin Emerg Drugs 2022. [PMID: 35642526 DOI: 10.1080/14728214.2022.2083107] [Reference Citation Analysis]
89 Ando Y, Hayashi T, Sugimoto R, Nishibe S, Ito K, Kawada K, Ikeda Y, Yamada S, Imaizumi K. Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. Invest New Drugs 2020;38:1200-6. [PMID: 31823160 DOI: 10.1007/s10637-019-00881-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
90 Kim BH, Park J. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. J Liver Cancer 2021;21:124-38. [DOI: 10.17998/jlc.2021.09.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Tang Z, Yang Y, Chen W, Li E, Liang T. Demethylation at enhancer upregulates MCM2 and NUP37 expression predicting poor survival in hepatocellular carcinoma patients. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03249-2] [Reference Citation Analysis]
92 Cucarull B, Tutusaus A, Rider P, Hernáez-Alsina T, Cuño C, García de Frutos P, Colell A, Marí M, Morales A. Hepatocellular Carcinoma: Molecular Pathogenesis and Therapeutic Advances. Cancers (Basel) 2022;14:621. [PMID: 35158892 DOI: 10.3390/cancers14030621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
93 Endo Y, Shimazu M, Sakuragawa T, Uchi Y, Edanami M, Sunamura K, Ozawa S, Chiba N, Kawachi S. Successful treatment with laparoscopic surgery and sequential multikinase inhibitor therapy for hepatocellular carcinoma: A case report. WJGS 2022;14:260-7. [DOI: 10.4240/wjgs.v14.i3.260] [Reference Citation Analysis]
94 Cammarota A, Zanuso V, D'Alessio A, Pressiani T, Bozzarelli S, Personeni N, Rimassa L. The dual checkpoint blockade in unresectable hepatocellular carcinoma: Opportunities emerging in clinical trials. Expert Opin Investig Drugs 2022. [PMID: 35152830 DOI: 10.1080/13543784.2022.2042253] [Reference Citation Analysis]
95 Chen B, Garmire L, Calvisi DF, Chua MS, Kelley RK, Chen X. Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2020;17:238-51. [PMID: 31900465 DOI: 10.1038/s41575-019-0240-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 14.5] [Reference Citation Analysis]
96 Motegi S, Yokoo T, Nozawa R, Azumi R, Kawata Y, Ogawa K, Setsu T, Mizuno KI, Nishino K, Umezu H, Kawai H, Suda T, Terai S. Long-term survival of 11 years with multidisciplinary therapy for hepatocellular carcinoma metastasis to the ovary and peritoneum: a case report. Clin J Gastroenterol 2021;14:1211-20. [PMID: 33978943 DOI: 10.1007/s12328-021-01434-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
97 Zhou K, Fountzilas C. Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E861. [PMID: 31234316 DOI: 10.3390/cancers11060861] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
98 Frankul L, Frenette C. Hepatocellular Carcinoma: Downstaging to Liver Transplantation as Curative Therapy. J Clin Transl Hepatol. 2021;9:220-226. [PMID: 34007804 DOI: 10.14218/jcth.2020.00037] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
99 Zeng Z, Yang B, Liao ZY. Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma. Oncol Lett 2020;20:45. [PMID: 32802167 DOI: 10.3892/ol.2020.11909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
100 Kudo M. A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE. Liver Cancer 2019;8:299-311. [PMID: 31768341 DOI: 10.1159/000502905] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
101 Yang PM, Lin LS, Liu TP. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells. Biomolecules 2020;10:E117. [PMID: 31936661 DOI: 10.3390/biom10010117] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
102 Roviello G, Casadei-Gardini A, Nobili S, Mini E, Fancelli S. Defining the Ideal Patient with Hepatocellular Carcinoma for Second-Line Treatment. J Oncol 2020;2020:8024124. [PMID: 32655640 DOI: 10.1155/2020/8024124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Eso Y, Seno H. Synergistic effects of anti-angiogenesis and immune checkpoint blockade - a new era of systemic chemotherapy for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2021;20:493-5. [PMID: 33906802 DOI: 10.1016/j.hbpd.2021.04.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Trojan J. Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Drugs 2020;80:1203-10. [PMID: 32671719 DOI: 10.1007/s40265-020-01361-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
105 Swed B, Ryan K, Gandarilla O, Shah MA, Brar G. Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma: A case report demonstrating that anti-VEGF therapy overcomes resistance to checkpoint inhibition. Medicine (Baltimore) 2021;100:e26471. [PMID: 34160456 DOI: 10.1097/MD.0000000000026471] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Kudo M, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer DH, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Yau T, Gurary EB, Siegel AB, Wang A, Cheng AL, Zhu AX; KEYNOTE-224 Investigators. Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib. Eur J Cancer 2022;167:1-12. [PMID: 35364421 DOI: 10.1016/j.ejca.2022.02.009] [Reference Citation Analysis]
107 Craig AJ, von Felden J, Garcia-Lezana T, Sarcognato S, Villanueva A. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17:139-152. [PMID: 31792430 DOI: 10.1038/s41575-019-0229-4] [Cited by in Crossref: 104] [Cited by in F6Publishing: 115] [Article Influence: 34.7] [Reference Citation Analysis]
108 Girardi DM, Pacífico JPM, Guedes de Amorim FPL, Dos Santos Fernandes G, Teixeira MC, Pereira AAL. Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives. Pharmaceuticals (Basel) 2020;14:28. [PMID: 33396181 DOI: 10.3390/ph14010028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
109 Catanese S, Lordick F. Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind? Ann Transl Med 2020;8:1701. [PMID: 33490213 DOI: 10.21037/atm-20-4438] [Reference Citation Analysis]
110 Zhu AX, Nipp RD, Finn RS, Galle PR, Llovet JM, Blanc JF, Okusaka T, Chau I, Cella D, Girvan A, Gable J, Bowman L, Wang C, Hsu Y, Abada PB, Kudo M. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials. ESMO Open 2020;5:e000797. [PMID: 32817068 DOI: 10.1136/esmoopen-2020-000797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
111 Chu PY, Chan SH. Cure the Incurable? Recent Breakthroughs in Immune Checkpoint Blockade for Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5295. [PMID: 34771459 DOI: 10.3390/cancers13215295] [Reference Citation Analysis]
112 Wang D, Yang X, Lin J, Bai Y, Long J, Yang X, Seery S, Zhao H. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials. Therap Adv Gastroenterol 2020;13:1756284820932483. [PMID: 32636928 DOI: 10.1177/1756284820932483] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
113 Riechelmann RP, Peixoto RD, Fernandes GDS, Weschenfelder RF, Prolla G, Filho DR, Andrade AC, Crosara M, Rego JFM, Gansl RC, Coimbra F, Aguiar S Jr, Carvalho E, Hoff PM, Coutinho AK. Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group. Ecancermedicalscience 2020;14:1048. [PMID: 32565901 DOI: 10.3332/ecancer.2020.1048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
114 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y; Real-life Practice Experts for HCC (RELPEC) Study Group and the HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan). Platelet-lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. Eur J Gastroenterol Hepatol 2021;32:261-8. [PMID: 32282541 DOI: 10.1097/MEG.0000000000001734] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
115 Nault JC, Villanueva A. Biomarkers for Hepatobiliary Cancers. Hepatology 2021;73 Suppl 1:115-27. [PMID: 32045030 DOI: 10.1002/hep.31175] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 37.0] [Reference Citation Analysis]
116 Personeni N, Pressiani T, D'Alessio A, Prete MG, Bozzarelli S, Terracciano L, Dal Buono A, Capogreco A, Aghemo A, Lleo A, Lutman RF, Roncalli M, Giordano L, Santoro A, Di Tommaso L, Rimassa L. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:5665. [PMID: 34830823 DOI: 10.3390/cancers13225665] [Reference Citation Analysis]
117 Fan W, Yang X, Huang F, Tong X, Zhu L, Wang S. Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer. Oncol Lett 2019;18:3218-26. [PMID: 31452799 DOI: 10.3892/ol.2019.10673] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
118 Gupta M, Iyer RV. Hepatocellular Carcinoma: Special Issue Highlights. Cancers (Basel) 2020;12:E2026. [PMID: 32722037 DOI: 10.3390/cancers12082026] [Reference Citation Analysis]
119 Dong M, Wang R, Sun P, Zhang D, Zhang Z, Zhang J, Tse G, Zhong L. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs. Oncol Lett 2021;21:315. [PMID: 33692847 DOI: 10.3892/ol.2021.12576] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
120 Kudo M. A Paradigm Change in the Treatment Strategy for Hepatocellular Carcinoma. Liver Cancer 2020;9:367-77. [PMID: 32999864 DOI: 10.1159/000507934] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
121 An L, Liao H, Yuan K. Efficacy and Safety of Second-line Treatments in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: A Meta-analysis. J Clin Transl Hepatol 2021;9:868-77. [PMID: 34966650 DOI: 10.14218/JCTH.2021.00054] [Reference Citation Analysis]
122 Finn RS, Zhu AX. Evolution of Systemic Therapy for Hepatocellular Carcinoma. Hepatology 2021;73 Suppl 1:150-7. [PMID: 32380571 DOI: 10.1002/hep.31306] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 27.0] [Reference Citation Analysis]
123 Saung MT, Pelosof L, Casak S, Donoghue M, Lemery S, Yuan M, Rodriguez L, Schotland P, Chuk M, Davis G, Goldberg KB, Theoret MR, Pazdur R, Fashoyin-Aje L. FDA Approval Summary: Nivolumab Plus Ipilimumab for the Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib. Oncologist 2021;26:797-806. [PMID: 33973307 DOI: 10.1002/onco.13819] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
124 Zhang Y, Huang G, Miao H, Song Z, Zhang X, Fan W, Wang Y, Li J, Chen Y. Apatinib treatment may improve survival outcomes of patients with hepatitis B virus-related sorafenib-resistant hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920937422. [PMID: 32754228 DOI: 10.1177/1758835920937422] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
126 Geh D, Manas DM, Reeves HL. Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians. Hepatobiliary Surg Nutr 2021;10:59-75. [PMID: 33575290 DOI: 10.21037/hbsn.2019.08.08] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
127 Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM, Rousseau B. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer 2019;7:333. [PMID: 31783782 DOI: 10.1186/s40425-019-0824-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 13.0] [Reference Citation Analysis]
128 Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Tsurusaki M, Nishida N. Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD-1/PD-L1 Checkpoint Blockade. Cancers (Basel) 2020;12:E3048. [PMID: 33092011 DOI: 10.3390/cancers12103048] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
129 Rimassa L, Pressiani T, Merle P. Response to the Comments on Rimassa et al.: "Systemic Treatment Options in Hepatocellular Carcinoma". Liver Cancer 2020;9:223-4. [PMID: 32399436 DOI: 10.1159/000503302] [Reference Citation Analysis]
130 Takahashi A, Moriguchi M, Seko Y, Shima T, Mitsumoto Y, Takashima H, Kimura H, Fujii H, Ishikawa H, Takaharu Y, Ishiba H, Morita A, Jo M, Nagao Y, Arai M, Hara T, Okajima A, Muramatsu A, Yoshinami N, Nakajima T, Mitsuyoshi H, Umemura A, Nishikawa T, Yamaguchi K, Okanoue T, Itoh Y. Early Tumor Shrinkage as a Predictive Factor for Outcomes in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Analysis. Cancers (Basel) 2020;12:E754. [PMID: 32209994 DOI: 10.3390/cancers12030754] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
131 Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 2020;77:1745-70. [PMID: 31690961 DOI: 10.1007/s00018-019-03351-7] [Cited by in Crossref: 157] [Cited by in F6Publishing: 151] [Article Influence: 52.3] [Reference Citation Analysis]
132 Amaro CP, Tam VC. Management of hepatocellular carcinoma after progression on first-line systemic treatment: defining the optimal sequencing strategy in second line and beyond. Curr Oncol 2020;27:S173-80. [PMID: 33343211 DOI: 10.3747/co.27.7103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
133 Voesch S, Bitzer M, Malek N. [Clinical relevance of the new S3 guideline on hepatocellular carcinoma and biliary tract cancer for practitioners]. Radiologe 2022. [PMID: 35147708 DOI: 10.1007/s00117-022-00970-3] [Reference Citation Analysis]
134 Rimini M, Yoo C, Lonardi S, Masi G, Granito A, Bang Y, Rizzato MD, Vivaldi C, Ielasi L, Kim HD, Bergamo F, Salani F, Leoni S, Ryoo BY, Ryoo MH, Burgio V, Cascinu S, Casadei-Gardini A. Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience. Target Oncol 2021;16:653-61. [PMID: 34491510 DOI: 10.1007/s11523-021-00834-1] [Reference Citation Analysis]
135 Sorokin M, Poddubskaya E, Baranova M, Glusker A, Kogoniya L, Markarova E, Allina D, Suntsova M, Tkachev V, Garazha A, Sekacheva M, Buzdin A. RNA sequencing profiles and diagnostic signatures linked with response to ramucirumab in gastric cancer. Cold Spring Harb Mol Case Stud 2020;6:a004945. [PMID: 32060041 DOI: 10.1101/mcs.a004945] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
136 Shomura M, Okabe H, Sato E, Fukai K, Shiraishi K, Hirose S, Tsuruya K, Arase Y, Anzai K, Kagawa T. Hypothyroidism is a Predictive Factor for Better Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Undergoing Lenvatinib Therapy. Cancers (Basel) 2020;12:E3078. [PMID: 33105621 DOI: 10.3390/cancers12113078] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
137 Cabrera R, Singal AG, Colombo M, Kelley RK, Lee H, Mospan AR, Meyer T, Newell P, Parikh ND, Sangro B, Reddy KR, Watkins S, Zink RC, Di Bisceglie AM. A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-HCC. Hepatol Commun 2021;5:538-47. [PMID: 33681685 DOI: 10.1002/hep4.1652] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
138 Wu WC, Lin TY, Chen MH, Hung YP, Liu CA, Lee RC, Huang YH, Chao Y, Chen SC. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience. Invest New Drugs 2022. [PMID: 35477812 DOI: 10.1007/s10637-022-01248-0] [Reference Citation Analysis]
139 Mani SKK, Yan B, Cui Z, Sun J, Utturkar S, Foca A, Fares N, Durantel D, Lanman N, Merle P, Kazemian M, Andrisani O. Restoration of RNA helicase DDX5 suppresses hepatitis B virus (HBV) biosynthesis and Wnt signaling in HBV-related hepatocellular carcinoma. Theranostics 2020;10:10957-72. [PMID: 33042264 DOI: 10.7150/thno.49629] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
140 Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. [PMID: 31655607 DOI: 10.1186/s13045-019-0794-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
141 Hsu PY, Cheng TS, Chuang SC, Chang WT, Liang PC, Hsu CT, Wei YJ, Jang TY, Yeh ML, Huang CI, Lin YH, Wang CW, Hsieh MY, Hou NJ, Hsieh MH, Tsai YS, Ko YM, Lin CC, Chen KY, Dai CY, Lin ZY, Chen SC, Huang JF, Chuang WL, Huang CF, Yu ML. Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. Cancer Med 2021. [PMID: 34786871 DOI: 10.1002/cam4.4430] [Reference Citation Analysis]
142 Chen MH, Lu SN, Chen CH, Lin PC, Jiang JK, D'yachkova Y, Lukanowski M, Cheng R, Chen LT. How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers? Cancers (Basel) 2021;13:3536. [PMID: 34298750 DOI: 10.3390/cancers13143536] [Reference Citation Analysis]
143 El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, Millang B, Ma J, O'Reilly EM, Abou-Alfa GK. Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib. Cancer Med 2020;9:7453-9. [PMID: 32841541 DOI: 10.1002/cam4.3389] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
144 Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Nakamura S, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y. Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. Liver Int 2020;40:968-76. [PMID: 32064740 DOI: 10.1111/liv.14405] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 10.0] [Reference Citation Analysis]
145 Carloni R, Rizzo A, Ricci AD, Frega G, Federico AD, Palloni A, Marco MD, Gadaleta-Caldarola G, Brandi G. Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35109664 DOI: 10.2217/fon-2021-0905] [Reference Citation Analysis]
146 Gong J, Chuang J, Cho M, Toomey K, Hendifar A, Li D. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E5232. [PMID: 32718047 DOI: 10.3390/ijms21155232] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
147 Lee C, Cheung ST. STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31731457 DOI: 10.3390/cancers11111646] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]
148 Wu CJ, Lee PC, Hung YW, Lee CJ, Chi CT, Lee IC, Hou MC, Huang YH. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma. Cancer Immunol Immunother 2022. [PMID: 35347395 DOI: 10.1007/s00262-022-03185-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Long HY, Huang TY, Xie XY, Long JT, Liu BX. Treatment strategies for hepatocellular carcinoma with extrahepatic metastasis. World J Clin Cases 2021; 9(21): 5754-5768 [PMID: 34368295 DOI: 10.12998/wjcc.v9.i21.5754] [Reference Citation Analysis]
150 Meyers BM, Knox JJ, Cosby R, Beecroft J, Chan KK, Coburn N, Feld JJ, Jonker D, Mahmud A, Ringash J. Non-surgical management of advanced hepatocellular carcinoma: A systematic review by Cancer Care Ontario. CanLivJ 2021;4:257-74. [DOI: 10.3138/canlivj-2020-0039] [Reference Citation Analysis]
151 Ladanie A, Schmitt AM, Speich B, Naudet F, Agarwal A, Pereira TV, Sclafani F, Herbrand AK, Briel M, Martin-Liberal J, Schmid T, Ewald H, Ioannidis JPA, Bucher HC, Kasenda B, Hemkens LG. Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016. JAMA Netw Open 2020;3:e2024406. [PMID: 33170262 DOI: 10.1001/jamanetworkopen.2020.24406] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
152 Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int 2021;41:598-607. [PMID: 33188713 DOI: 10.1111/liv.14731] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
153 Chen R, Zhang Y. EPDR1 correlates with immune cell infiltration in hepatocellular carcinoma and can be used as a prognostic biomarker. J Cell Mol Med 2020;24:12107-18. [PMID: 32935479 DOI: 10.1111/jcmm.15852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
154 Tohyama T, Tamura K, Takai A, Nishimura K, Kido T, Takada Y. Transmediastinal, intrapericardial inferior vena cava approach based on anatomical landmarks for hepatectomy using total hepatic vascular exclusion. Langenbecks Arch Surg 2021. [PMID: 34427752 DOI: 10.1007/s00423-021-02246-1] [Reference Citation Analysis]
155 Bejjani A, Finn RS. The Place of Novel Therapies in the American Association for the Study of Liver Diseases Guidelines for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2019;14:51-5. [PMID: 31508220 DOI: 10.1002/cld.815] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
156 Yamazoe T, Mori T, Yoshio S, Kanto T. Hepatocyte ploidy and pathological mutations in hepatocellular carcinoma: impact on oncogenesis and therapeutics. Glob Health Med 2020;2:273-81. [PMID: 33330821 DOI: 10.35772/ghm.2020.01089] [Reference Citation Analysis]
157 Tovoli F, Ielasi L, Casadei-Gardini A, Granito A, Foschi FG, Rovesti G, Negrini G, Orsi G, Renzulli M, Piscaglia F. Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients. J Hepatol 2019;71:1175-83. [PMID: 31449860 DOI: 10.1016/j.jhep.2019.08.015] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 9.3] [Reference Citation Analysis]
158 Su Y, Liu Y, Hsiao C, Hsu C, Chen L. Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma. JHC 2022;Volume 9:517-36. [DOI: 10.2147/jhc.s220978] [Reference Citation Analysis]
159 Xie H, Alem Glison DM, Kim RD. FGFR4 inhibitors for the treatment of hepatocellular carcinoma: a synopsis of therapeutic potential. Expert Opin Investig Drugs 2021;:1-8. [PMID: 34913780 DOI: 10.1080/13543784.2022.2017879] [Reference Citation Analysis]
160 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
161 Pelizzaro F, Gambato M, Gringeri E, Vitale A, Cillo U, Farinati F, Burra P, Russo FP. Management of Hepatocellular Carcinoma Recurrence after Liver Transplantation. Cancers (Basel) 2021;13:4882. [PMID: 34638365 DOI: 10.3390/cancers13194882] [Reference Citation Analysis]
162 Díaz-González Á, Sapena V, Boix L, Torres F, Sanduzzi-Zamparelli M, Da Fonseca LG, LLarch N, Iserte G, Guedes C, Muñoz-Martínez S, Darnell A, Belmonte E, Rimola J, Forner A, Ayuso C, Bruix J, Reig M. Early diarrhoea under sorafenib as a marker to consider the early migration to second-line drugs. United European Gastroenterol J 2021;9:655-61. [PMID: 34228394 DOI: 10.1002/ueg2.12111] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
163 Schipilliti FM, Garajová I, Rovesti G, Balsano R, Piacentini F, Dominici M, Gelsomino F. The Growing Skyline of Advanced Hepatocellular Carcinoma Treatment: A Review. Pharmaceuticals (Basel) 2021;14:43. [PMID: 33429973 DOI: 10.3390/ph14010043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
164 Cammarota A, Zanuso V, D’alessio A, Pressiani T, Personeni N, Rimassa L. Cabozantinib plus atezolizumab for the treatment of advanced hepatocellular carcinoma: Shedding light on the preclinical rationale and clinical trials. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2032641] [Reference Citation Analysis]
165 Rimassa L, Pressiani T, Merle P. Systemic Treatment Options in Hepatocellular Carcinoma. Liver Cancer. 2019;8:427-446. [PMID: 31799201 DOI: 10.1159/000499765] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 11.0] [Reference Citation Analysis]
166 Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial. Liver Cancer 2021;10:275-84. [PMID: 34239813 DOI: 10.1159/000515553] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Fukushima T, Morimoto M, Ueno M, Kubota K, Uojima H, Hidaka H, Chuma M, Numata K, Tsuruya K, Hirose S, Kagawa T, Hattori N, Watanabe T, Matsunaga K, Yamamoto K, Tanaka K, Maeda S. Comparative study between sorafenib and lenvatinib as the first-line therapy in the sequential treatment of unresectable hepatocellular carcinoma in a real-world setting. JGH Open 2022;6:29-35. [PMID: 35071785 DOI: 10.1002/jgh3.12691] [Reference Citation Analysis]
168 Yoon JK, Choi JY, Rhee H, Park YN. MRI features of histologic subtypes of hepatocellular carcinoma: correlation with histologic, genetic, and molecular biologic classification. Eur Radiol 2022. [PMID: 35258675 DOI: 10.1007/s00330-022-08643-4] [Reference Citation Analysis]
169 Ahn JC, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, Sundaram V, Kosari K, Nissen N, Gong J, Hendifar A, Roberts LR, Abou-Alfa GK, Singal AG, Yang JD. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology 2022. [PMID: 35429171 DOI: 10.1002/hep.32527] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Koroki K, Ogasawara S, Ooka Y, Kanzaki H, Kanayama K, Maruta S, Maeda T, Yokoyama M, Wakamatsu T, Inoue M, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Yasui S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kuboki S, Ohtsuka M, Miyazaki M, Yokosuka O, Kato N. Analyses of Intermediate-Stage Hepatocellular Carcinoma Patients Receiving Transarterial Chemoembolization prior to Designing Clinical Trials. Liver Cancer 2020;9:596-612. [PMID: 33083283 DOI: 10.1159/000508809] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
171 Ostroumov D, Duong S, Wingerath J, Woller N, Manns MP, Timrott K, Kleine M, Ramackers W, Roessler S, Nahnsen S, Czemmel S, Dittrich-Breiholz O, Eggert T, Kühnel F, Wirth TC. Transcriptome Profiling Identifies TIGIT as a Marker of T-Cell Exhaustion in Liver Cancer. Hepatology 2021;73:1399-418. [PMID: 32716559 DOI: 10.1002/hep.31466] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
172 Abd El Aziz MA, Facciorusso A, Nayfeh T, Saadi S, Elnaggar M, Cotsoglou C, Sacco R. Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma. Vaccines (Basel) 2020;8:E616. [PMID: 33086471 DOI: 10.3390/vaccines8040616] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
173 Kosaka Y, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Ando Y, Suehiro Y, Yamaoka K, Fujii Y, Uchikawa S, Ono A, Yamauchi M, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Successful multimodality treatment for advanced hepatocellular carcinoma with tumor thrombosis of the main portal trunk: a case study. Clin J Gastroenterol 2021. [PMID: 34291386 DOI: 10.1007/s12328-021-01481-9] [Reference Citation Analysis]
174 Kudo M. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1089. [PMID: 32349374 DOI: 10.3390/cancers12051089] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 13.0] [Reference Citation Analysis]
175 Kudo M, Ikeda M, Galle PR, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX. Ramucirumab in patients with advanced hepatocellular carcinoma and elevated α-fetoprotein: Outcomes by treatment-emergent ascites. Hepatol Res 2021;51:715-21. [PMID: 33743189 DOI: 10.1111/hepr.13638] [Reference Citation Analysis]
176 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
177 Alqahtani A, Khan Z, Alloghbi A, Said Ahmed TS, Ashraf M, Hammouda DM. Hepatocellular Carcinoma: Molecular Mechanisms and Targeted Therapies. Medicina (Kaunas) 2019;55:E526. [PMID: 31450841 DOI: 10.3390/medicina55090526] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
178 Yoo C, Kim JH, Ryu MH, Park SR, Lee D, Kim KM, Shim JH, Lim YS, Lee HC, Lee J, Tai D, Chan SL, Ryoo BY. Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. Liver Cancer 2021;10:107-14. [PMID: 33977087 DOI: 10.1159/000512781] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
179 Oura K, Takuma K, Nakahara M, Tadokoro T, Fujita K, Mimura S, Tani J, Morishita A, Kobara H, Masaki T. Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature. Mol Clin Oncol 2021;15:154. [PMID: 34178325 DOI: 10.3892/mco.2021.2316] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
180 Personeni N, Pressiani T, Rimassa L. Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma. Health Sci Rep 2020;3:e147. [PMID: 32166192 DOI: 10.1002/hsr2.147] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
181 Wu S, Xie Z, Yan L, Liu X, Zhang Y, Wang D, Dong J, Sun H. The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinoma. BMC Immunol 2022;23. [DOI: 10.1186/s12865-022-00502-7] [Reference Citation Analysis]
182 Biolato M, Galasso T, Marrone G, Miele L, Grieco A. Upper Limits of Downstaging for Hepatocellular Carcinoma in Liver Transplantation. Cancers (Basel) 2021;13:6337. [PMID: 34944957 DOI: 10.3390/cancers13246337] [Reference Citation Analysis]
183 Guo LF, Gao G, Yuan Z. Detection of Dysplastic Liver Nodules in Patients with Cirrhosis Using the Multi-Arterial CAIPIRINHA-Dixon-TWIST-Volume-Interpolated Breath-Hold Examination (MA-CDT-VIBE) Technique in Dynamic Contrast-Enhanced Magnetic Resonance Imaging. Med Sci Monit 2020;26:e922618. [PMID: 32562415 DOI: 10.12659/MSM.922618] [Reference Citation Analysis]
184 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
185 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
186 Xu G, Jin B, Xian X, Yang H, Zhao H, Du S, Makuuchi M, Pawlik TM, Mao Y. Evolutions in the Management of Hepatocellular Carcinoma over Last 4 Decades: An Analysis from the 100 Most Influential Articles in the Field. Liver Cancer 2021;10:137-50. [PMID: 33977090 DOI: 10.1159/000513412] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
187 Cabibbo G, Singal AG. The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)02226-1. [PMID: 34843751 DOI: 10.1016/j.jhep.2021.11.021] [Reference Citation Analysis]
188 Fründt T, Krause L, Hussey E, Steinbach B, Köhler D, von Felden J, Schulze K, Lohse AW, Wege H, Schwarzenbach H. Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers (Basel) 2021;13:2484. [PMID: 34069692 DOI: 10.3390/cancers13102484] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
189 Sherrow C, Attwood K, Zhou K, Mukherjee S, Iyer R, Fountzilas C. Sequencing Systemic Therapy Pathways for Advanced Hepatocellular Carcinoma: A Cost Effectiveness Analysis. Liver Cancer 2020;9:549-62. [PMID: 33083280 DOI: 10.1159/000508485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, Bie P, Liu L, Wen T, Han G, Wang M, Liu R, Lu L, Ren Z, Chen M, Zeng Z, Liang P, Liang C, Chen M, Yan F, Wang W, Ji Y, Yun J, Cai D, Chen Y, Cheng W, Cheng S, Dai C, Guo W, Hua B, Huang X, Jia W, Li Y, Li Y, Liang J, Liu T, Lv G, Mao Y, Peng T, Ren W, Shi H, Shi G, Tao K, Wang W, Wang X, Wang Z, Xiang B, Xing B, Xu J, Yang J, Yang J, Yang Y, Yang Y, Ye S, Yin Z, Zhang B, Zhang B, Zhang L, Zhang S, Zhang T, Zhao Y, Zheng H, Zhu J, Zhu K, Liu R, Shi Y, Xiao Y, Dai Z, Teng G, Cai J, Wang W, Cai X, Li Q, Shen F, Qin S, Dong J, Fan J. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer 2020;9:682-720. [PMID: 33442540 DOI: 10.1159/000509424] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 8.5] [Reference Citation Analysis]
191 Liu ZL, Zhu LL, Liu JH, Pu ZY, Ruan ZP, Chen J. Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma. Aging (Albany NY) 2020;12:25172-88. [PMID: 33223512 DOI: 10.18632/aging.104119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
192 Deng X, Luo T, Zhang X, Li Y, Xie L, Jiang W, Liu L, Wang Z. Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer. European Journal of Medicinal Chemistry 2022;237:114376. [DOI: 10.1016/j.ejmech.2022.114376] [Reference Citation Analysis]
193 Nishida T, Kataoka H. Glypican 3-Targeted Therapy in Hepatocellular Carcinoma. Cancers (Basel). 2019;11. [PMID: 31510063 DOI: 10.3390/cancers11091339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
194 Yen CC, Yen CJ. Safety of ramucirumab treatment in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein. Expert Opin Drug Saf 2021;:1-10. [PMID: 34668832 DOI: 10.1080/14740338.2022.1995353] [Reference Citation Analysis]
195 Heinrich S, Castven D, Galle PR, Marquardt JU. Translational Considerations to Improve Response and Overcome Therapy Resistance in Immunotherapy for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2495. [PMID: 32899197 DOI: 10.3390/cancers12092495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
196 Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T. The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study. Cancers (Basel) 2021;13:2002. [PMID: 33919277 DOI: 10.3390/cancers13092002] [Reference Citation Analysis]
197 Rovesti G, Orsi G, Kalliopi A, Vivaldi C, Marisi G, Faloppi L, Foschi FG, Silvestris N, Pecora I, Aprile G, Molinaro E, Riggi L, Ulivi P, Canale M, Cucchetti A, Tamburini E, Ercolani G, Fornaro L, Andreone P, Zavattari P, Scartozzi M, Cascinu S, Casadei-Gardini A. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. Gastrointest Tumors 2019;6:92-107. [PMID: 31768353 DOI: 10.1159/000502714] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 5.3] [Reference Citation Analysis]
198 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
199 Wang C, Cao Y, Yang C, Bernards R, Qin W. Exploring liver cancer biology through functional genetic screens. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34163045 DOI: 10.1038/s41575-021-00465-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Fujii Y, Ono A, Hayes CN, Aikata H, Yamauchi M, Uchikawa S, Kodama K, Teraoka Y, Fujino H, Nakahara T, Murakami E, Miki D, Okamoto W, Kawaoka T, Tsuge M, Imamura M, Chayama K. Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib. J Exp Clin Cancer Res 2021;40:215. [PMID: 34174931 DOI: 10.1186/s13046-021-02016-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
201 Jain A, Chitturi S, Peters G, Yip D. Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice. World J Hepatol 2021; 13(9): 1132-1142 [PMID: 34630880 DOI: 10.4254/wjh.v13.i9.1132] [Reference Citation Analysis]
202 Shokoohian B, Negahdari B, Aboulkheyr Es H, Abedi-Valugerdi M, Baghaei K, Agarwal T, Maiti TK, Hassan M, Najimi M, Vosough M. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. J Cell Mol Med 2021;25:8602-14. [PMID: 34423899 DOI: 10.1111/jcmm.16875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
203 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis. Hepatol Commun 2020;4:1218-28. [PMID: 32766480 DOI: 10.1002/hep4.1535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
204 Chen YY, Wang CC, Liu YW, Li WF, Chen YH. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib. PeerJ 2020;8:e10382. [PMID: 33240675 DOI: 10.7717/peerj.10382] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Kuo YH, Lu SN, Chen YY, Kee KM, Yen YH, Hung CH, Hu TH, Chen CH, Wang JH. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front Oncol 2021;11:737767. [PMID: 34760699 DOI: 10.3389/fonc.2021.737767] [Reference Citation Analysis]
206 Lindblad KE, Ruiz de Galarreta M, Lujambio A. Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers. Front Immunol 2021;12:642958. [PMID: 33981303 DOI: 10.3389/fimmu.2021.642958] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
207 Monge C, Xie C, Steinberg SM, Greten TF. Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:507-12. [PMID: 34104639 DOI: 10.2147/JHC.S311496] [Reference Citation Analysis]
208 Campani C, Rimassa L, Personeni N, Marra F. Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner. Ann Transl Med 2020;8:1532. [PMID: 33313277 DOI: 10.21037/atm-20-3788] [Reference Citation Analysis]
209 Han S, Kim DY. Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma. Clin Mol Hepatol 2020;26:305-8. [PMID: 32646205 DOI: 10.3350/cmh.2020.0096] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
210 Lee-Ying R, Ahmed O, Ahmed S, Ahmed S, Bathe OF, Brunet B, Dawson L, Davies J, Gordon V, Hebbard P, Kasnik J, Kim CA, Le D, Lee MKC, Lim H, McGhie JP, Mulder K, Park J, Renouf D, Tam V, Visser R, Wong RPW, Zaidi A, Doll C. Report from the 21st Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Calgary, Alberta; 20-21 September 2019. Curr Oncol 2021;28:3629-48. [PMID: 34590606 DOI: 10.3390/curroncol28050310] [Reference Citation Analysis]
211 Kudo M. Targeted and immune therapies for hepatocellular carcinoma: Predictions for 2019 and beyond. World J Gastroenterol 2019; 25(7): 789-807 [PMID: 30809080 DOI: 10.3748/wjg.v25.i7.789] [Cited by in CrossRef: 77] [Cited by in F6Publishing: 70] [Article Influence: 25.7] [Reference Citation Analysis]
212 Maruta S, Ogasawara S, Ooka Y, Obu M, Inoue M, Itokawa N, Haga Y, Seki A, Okabe S, Azemoto R, Itobayashi E, Atsukawa M, Sugiura N, Mizumoto H, Koroki K, Kanayama K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Suzuki E, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato N. Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer. 2020;9:382-396. [PMID: 32999866 DOI: 10.1159/000507022] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
213 D'alessio A, Fulgenzi CAM. Treating patients with advanced hepatocellular carcinoma and impaired liver function: Broadening the reach of anti‐cancer therapy. Liver Cancer International 2021;2:31-2. [DOI: 10.1002/lci2.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
214 Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer 2021;10:451-60. [PMID: 34721507 DOI: 10.1159/000516605] [Reference Citation Analysis]
215 Wang C, Lv Y, Sha Z, Zhang J, Wu J, Qi Y, Guo Z. Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway. J Hepatocell Carcinoma 2021;8:1643-53. [PMID: 35004391 DOI: 10.2147/JHC.S327258] [Reference Citation Analysis]
216 Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel) 2019;11:E1517. [PMID: 31601010 DOI: 10.3390/cancers11101517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
217 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
218 Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, Fabbrocini A, Petrillo A, Daniele B. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals (Basel) 2021;14:233. [PMID: 33800217 DOI: 10.3390/ph14030233] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
219 Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T. Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer 2021;10:181-223. [PMID: 34239808 DOI: 10.1159/000514174] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Giannini EG, Trevisani F. Ramucirumab as a second-line treatment for hepatocellular carcinoma: reaching out further to patients with elevated alpha-fetoprotein. Hepatobiliary Surg Nutr 2019;8:515-8. [PMID: 31673543 DOI: 10.21037/hbsn.2019.04.19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
221 Yano Y, Yamamoto A, Minami A, Momose K, Mimura T, Kim SK, Hayashi H, Kado T, Hirano H, Hirohata S, Yoon S, Nishi K, Tei H, Tanaka H, Oouchi S, Matsuura T, Yasutomi E, Hatazawa Y, Shiomi Y, Ueda Y, Kodama Y; Kobe Liver Conference (KLC). Significance of post‐progression therapy after tyrosine kinase inhibitors for advanced hepatocellular carcinoma. JGH Open. [DOI: 10.1002/jgh3.12772] [Reference Citation Analysis]
222 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
223 Kudo M. Sequential Therapy for Hepatocellular Carcinoma after Failure of Atezolizumab plus Bevacizumab Combination Therapy. Liver Cancer 2021;10:85-93. [PMID: 33977086 DOI: 10.1159/000514312] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
224 Trojan J, Mollon P, Daniele B, Marteau F, Martín L, Li Y, Xu Q, Piscaglia F, Zaucha R, Sarker D, Lim HY, Venerito M. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison. Adv Ther 2021;38:2472-90. [PMID: 33822328 DOI: 10.1007/s12325-021-01700-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
225 Kasuya K, Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Kajiwara A, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Eguchi Y, Hashimoto M, Kumada H. Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib. Intern Med 2021;60:345-51. [PMID: 32963154 DOI: 10.2169/internalmedicine.5185-20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
226 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
227 Lin CC, Yang TS, Yen CJ, Cheng R, Liu J, Hsu C. Safety and Preliminary Efficacy of Ramucirumab in Combination with FOLFOX4 in Patients with Advanced Hepatocellular Carcinoma: A Nonrandomized, Open-Label, Phase Ib Study. Oncologist 2020;25:e1921-9. [PMID: 33017497 DOI: 10.1002/onco.13550] [Reference Citation Analysis]
228 Manna D, Sarkar D. Non-Coding RNAs: Regulating Disease Progression and Therapy Resistance in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1243. [PMID: 32429062 DOI: 10.3390/cancers12051243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
229 Khare S, Khare T, Ramanathan R, Ibdah JA. Hepatocellular Carcinoma: The Role of MicroRNAs. Biomolecules 2022;12:645. [DOI: 10.3390/biom12050645] [Reference Citation Analysis]
230 Alqahtani SA, Sanai FM, Alolayan A, Abaalkhail F, Alsuhaibani H, Hassanain M, Alhazzani W, Alsuhaibani A, Algarni A, Forner A, Finn RS, Al-Hamoudi WK. Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma. Saudi J Gastroenterol 2020;26:S1-S40. [PMID: 33078723 DOI: 10.4103/sjg.SJG_477_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
231 Neureiter D, Stintzing S, Kiesslich T, Ocker M. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World J Gastroenterol 2019; 25(25): 3136-3150 [PMID: 31333307 DOI: 10.3748/wjg.v25.i25.3136] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
232 Saeed A, Hildebrand H, Park R, Al-Jumayli M, Abbasi S, Melancon T, Saeed A, Al-Rajabi R, Kasi A, Baranda J, Williamson S, Sun W. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. J Clin Med 2020;9:E2682. [PMID: 32824968 DOI: 10.3390/jcm9092682] [Reference Citation Analysis]
233 Xu B, Sun HC. Camrelizumab: an investigational agent for hepatocellular carcinoma. Expert Opin Investig Drugs 2021;:1-10. [PMID: 34937475 DOI: 10.1080/13543784.2022.2022121] [Reference Citation Analysis]
234 Ridder DA, Weinmann A, Schindeldecker M, Urbansky LL, Berndt K, Gerber TS, Lang H, Lotz J, Lackner KJ, Roth W, Straub BK. Comprehensive clinicopathologic study of alpha fetoprotein-expression in a large cohort of patients with hepatocellular carcinoma. Int J Cancer 2021. [PMID: 34894400 DOI: 10.1002/ijc.33898] [Reference Citation Analysis]
235 De Luca E, Marino D, Di Maio M. Ramucirumab, A Second-Line Option For Patients With Hepatocellular Carcinoma: A Review Of The Evidence. Cancer Manag Res 2020;12:3721-9. [PMID: 32547208 DOI: 10.2147/CMAR.S216220] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
236 Wada Y, Takami Y, Ryu T, Ureshino H, Imamura H, Sasaki S, Saitsu H. A Case of Advanced Hepatocellular Carcinoma with Partial Response after Continuous Ramucirumab Treatment beyond Radiological Progression. Case Rep Oncol 2020;13:379-84. [PMID: 32355493 DOI: 10.1159/000506331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Fan G, Wei X, Xu X. Is the era of sorafenib over? A review of the literature. Ther Adv Med Oncol 2020;12:1758835920927602. [PMID: 32518599 DOI: 10.1177/1758835920927602] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
238 Raees A, Kamran M, Özkan H, Jafri W. Updates on the Diagnosis and Management of Hepatocellular Carcinoma. Euroasian J Hepatogastroenterol 2021;11:32-40. [PMID: 34316462 DOI: 10.5005/jp-journals-10018-1335] [Reference Citation Analysis]
239 Winters AC, Bedier F, Saab S. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. Clin Liver Dis 2020;24:755-69. [PMID: 33012457 DOI: 10.1016/j.cld.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
240 Pomej K, Scheiner B, Park D, Bauer D, Balcar L, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2020;12:E2961. [PMID: 33066190 DOI: 10.3390/cancers12102961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
241 Rallis KS, Makrakis D, Ziogas IA, Tsoulfas G. Immunotherapy for advanced hepatocellular carcinoma: From clinical trials to real-world data and future advances. World J Clin Oncol 2022; 13(6): 448-472 [DOI: 10.5306/wjco.v13.i6.448] [Reference Citation Analysis]
242 Kaps L, Schuppan D. Targeting Cancer Associated Fibroblasts in Liver Fibrosis and Liver Cancer Using Nanocarriers. Cells 2020;9:E2027. [PMID: 32899119 DOI: 10.3390/cells9092027] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
243 Ruf B, Heinrich B, Greten TF. Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells. Cell Mol Immunol. 2021;18:112-127. [PMID: 33235387 DOI: 10.1038/s41423-020-00572-w] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
244 Raybould AL, Sanoff H. Combination Antiangiogenic and Immunotherapy for Advanced Hepatocellular Carcinoma: Evidence to Date. J Hepatocell Carcinoma 2020;7:133-42. [PMID: 32984090 DOI: 10.2147/JHC.S224938] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
245 Sas Z, Cendrowicz E, Weinhäuser I, Rygiel TP. Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options. Int J Mol Sci 2022;23:3778. [PMID: 35409139 DOI: 10.3390/ijms23073778] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Huang Y, Huang X, Zeng J, Lin J. Knockdown of MUC16 (CA125) Enhances the Migration and Invasion of Hepatocellular Carcinoma Cells. Front Oncol 2021;11:667669. [PMID: 34150633 DOI: 10.3389/fonc.2021.667669] [Reference Citation Analysis]
247 Kudo M, Han KH, Ye SL, Zhou J, Huang YH, Lin SM, Wang CK, Ikeda M, Chan SL, Choo SP, Miyayama S, Cheng AL. A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 2020;9:245-60. [PMID: 32647629 DOI: 10.1159/000507370] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 12.5] [Reference Citation Analysis]
248 Anand AC, Acharya SK. New Developments in the Treatment of Hepatocellular Carcinoma: The Concept of Adjuvant and Neoadjuvant Chemotherapy. J Clin Exp Hepatol 2021;11:284-7. [PMID: 33994710 DOI: 10.1016/j.jceh.2021.04.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 He W, Liao L, Hu D, Li B, Wang C, Qiu J, Liao Y, Liu W, Yang Z, Zhang Y, Yuan Y, Li K, Yuan Y, Zheng Y. Apatinib versus sorafenib in patients with advanced hepatocellular carcinoma: a preliminary study. Ann Transl Med 2020;8:1000. [PMID: 32953800 DOI: 10.21037/atm-20-5298] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
250 Alqahtani SA, Colombo MG. Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma . World J Gastrointest Oncol 2021; 13(12): 2038-2049 [DOI: 10.4251/wjgo.v13.i12.2038] [Reference Citation Analysis]
251 Raoul JL, Frenel JS, Raimbourg J, Gilabert M. Current options and future possibilities for the systemic treatment of hepatocellular carcinoma. Hepat Oncol 2019;6:HEP11. [PMID: 31244990 DOI: 10.2217/hep-2019-0001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
252 Shigesawa T, Suda G, Kimura M, Maehara O, Tokuchi Y, Kubo A, Yamada R, Furuya K, Baba M, Kitagataya T, Suzuki K, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N. Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. PLoS One 2021;16:e0247728. [PMID: 33647018 DOI: 10.1371/journal.pone.0247728] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
254 Childs A, Zakeri N, Ma YT, O'Rourke J, Ross P, Hashem E, Hubner RA, Hockenhull K, Iwuji C, Khan S, Palmer DH, Connor J, Swinson D, Darby S, Braconi C, Roques T, Yu D, Luong TV, Meyer T. Biopsy for advanced hepatocellular carcinoma: results of a multicentre UK audit. Br J Cancer 2021;125:1350-5. [PMID: 34526664 DOI: 10.1038/s41416-021-01535-2] [Reference Citation Analysis]
255 Rinaldi L, Vetrano E, Rinaldi B, Galiero R, Caturano A, Salvatore T, Sasso FC. HCC and Molecular Targeting Therapies: Back to the Future. Biomedicines 2021;9:1345. [PMID: 34680462 DOI: 10.3390/biomedicines9101345] [Reference Citation Analysis]
256 Shimada S, Tanaka S. Molecular targeted drugs, comprehensive classification and preclinical models for the implementation of precision immune oncology in hepatocellular carcinoma. Int J Clin Oncol 2022. [PMID: 35633441 DOI: 10.1007/s10147-022-02174-0] [Reference Citation Analysis]
257 Federico P, Petrillo A, Giordano P, Bosso D, Fabbrocini A, Ottaviano M, Rosanova M, Silvestri A, Tufo A, Cozzolino A, Daniele B. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Status and Novel Perspectives. Cancers (Basel) 2020;12:E3025. [PMID: 33080958 DOI: 10.3390/cancers12103025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
258 Foerster F, Galle PR. The Current Landscape of Clinical Trials for Systemic Treatment of HCC. Cancers (Basel) 2021;13:1962. [PMID: 33921731 DOI: 10.3390/cancers13081962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Yamamoto T, Imai N, Kuzuya T, Yokoyama S, Yamamoto K, Ito T, Ishizu Y, Honda T, Ishigami M. Changes in Body Composition Predict the Time to Treatment Failure of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma: A Pilot Retrospective Study. Nutrition and Cancer. [DOI: 10.1080/01635581.2022.2049322] [Reference Citation Analysis]
260 Lee CH, Lee YB, Kim MA, Jang H, Oh H, Kim SW, Cho EJ, Lee KH, Lee JH, Yu SJ, Yoon JH, Kim TY, Kim YJ. Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment. Clin Mol Hepatol 2020;26:328-39. [PMID: 32460459 DOI: 10.3350/cmh.2019.0049n] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
261 Sonbol MB, Riaz IB, Naqvi SAA, Almquist DR, Mina S, Almasri J, Shah S, Almader-Douglas D, Uson Junior PLS, Mahipal A, Ma WW, Jin Z, Mody K, Starr J, Borad MJ, Ahn DH, Murad MH, Bekaii-Saab T. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis. JAMA Oncol. 2020;6:e204930. [PMID: 33090186 DOI: 10.1001/jamaoncol.2020.4930] [Cited by in Crossref: 15] [Cited by in F6Publishing: 21] [Article Influence: 7.5] [Reference Citation Analysis]
262 Marinelli B, Cedillo M, Pasik SD, Charles D, Murthy S, Patel RS, Fischman A, Ranade M, Bishay V, Nowakowski S, Sung M, Marron T, Lookstein R, Schwartz M, Kim E. Safety and Efficacy of Locoregional Treatment during Immunotherapy with Nivolumab for Hepatocellular Carcinoma: A Retrospective Study of 41 Interventions in 29 Patients. J Vasc Interv Radiol 2020;31:1729-1738.e1. [PMID: 33012649 DOI: 10.1016/j.jvir.2020.07.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
263 Wang J, Pillai A. Systemic Therapy for Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2021;17:337-40. [PMID: 34136138 DOI: 10.1002/cld.1058] [Reference Citation Analysis]
264 Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 2020;6. [PMID: 33134550 DOI: 10.20517/2394-5079.2020.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
265 Hatanaka T, Naganuma A, Kakizaki S. Lenvatinib for Hepatocellular Carcinoma: A Literature Review. Pharmaceuticals (Basel) 2021;14:36. [PMID: 33418941 DOI: 10.3390/ph14010036] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
266 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
267 Kudo M, Okusaka T, Motomura K, Ohno I, Morimoto M, Seo S, Wada Y, Sato S, Yamashita T, Furukawa M, Aramaki T, Nadano S, Ohkawa K, Fujii H, Kudo T, Furuse J, Takai H, Homma G, Yoshikawa R, Zhu AX. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial. J Gastroenterol 2020;55:627-39. [PMID: 32107609 DOI: 10.1007/s00535-020-01668-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
268 D'Alessio A, Rimassa L, Cortellini A, Pinato DJ. PD-1 Blockade for Hepatocellular Carcinoma: Current Research and Future Prospects. J Hepatocell Carcinoma 2021;8:887-97. [PMID: 34386437 DOI: 10.2147/JHC.S284440] [Reference Citation Analysis]
269 Fessas P, Kaseb A, Wang Y, Saeed A, Szafron D, Jun T, Dharmapuri S, Rafeh Naqash A, Muzaffar M, Navaid M, Khan U, Lee C, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Benevento F, Hildebrand H, Pressiani T, Abugabal YI, Personeni N, Huang YH, Rimassa L, Ang C, Marron T, Pinato DJ. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study. J Immunother Cancer 2020;8:e001033. [PMID: 32868393 DOI: 10.1136/jitc-2020-001033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
270 Weinmann A, Galle PR. Role of immunotherapy in the management of hepatocellular carcinoma: current standards and future directions. Curr Oncol 2020;27:S152-64. [PMID: 33343209 DOI: 10.3747/co.27.7315] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
271 Calderaro J. Dual angiogenesis and PD-1 blockade in hepatocellular carcinoma. Hepatobiliary Surg Nutr 2020;9:350-2. [PMID: 32509827 DOI: 10.21037/hbsn.2019.10.37] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
272 Chuma M, Uojima H, Hattori N, Arase Y, Fukushima T, Hirose S, Kobayashi S, Ueno M, Tezuka S, Iwasaki S, Wada N, Kubota K, Tsuruya K, Shimma Y, Hiroki I, Takuya E, Tokoro C, Iwase S, Miura Y, Moriya S, Watanabe T, Hidaka H, Morimoto M, Numata K, Kusano C, Kagawa T, Maeda S. Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis. Hepatol Res 2021. [PMID: 34761470 DOI: 10.1111/hepr.13732] [Reference Citation Analysis]
273 Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, Waidmann O, Reiberger T, Müller C, Sieghart W, Trauner M, Weinmann A, Wege H, Trojan J, Peck-Radosavljevic M, Vogel A, Pinter M. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther 2019;49:1323-33. [PMID: 30980420 DOI: 10.1111/apt.15245] [Cited by in Crossref: 37] [Cited by in F6Publishing: 45] [Article Influence: 12.3] [Reference Citation Analysis]
274 Taketomi A. Hepatic Resection for Hepatocellular Carcinoma in the Era of Molecular-targeted Agents and Immune Checkpoint Inhibitors in Japan. JMA J 2021;4:241-5. [PMID: 34414318 DOI: 10.31662/jmaj.2021-0035] [Reference Citation Analysis]
275 Kawamura Y, Kobayashi M, Shindoh J, Kobayashi Y, Okubo S, Tominaga L, Kajiwara A, Kasuya K, Iritani S, Fujiyama S, Hosaka T, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Ikeda K, Arase Y, Hashimoto M, Kozuka T, Kumada H. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer 2020;9:756-70. [PMID: 33442544 DOI: 10.1159/000510299] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
276 Bang YH, Lee C, Yoo C, Chon HJ, Hong M, Kang B, Kim H, Park SR, Choi W, Choi J, Lee D, Shim JH, Kim KM, Lim Y, Lee HC, Ryu M, Ryoo B. Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. Ther Adv Med Oncol 2022;14:175883592210979. [DOI: 10.1177/17588359221097934] [Reference Citation Analysis]
277 Moehler M, Heo J, Lee HC, Tak WY, Chao Y, Paik SW, Yim HJ, Byun KS, Baron A, Ungerechts G, Jonker D, Ruo L, Cho M, Kaubisch A, Wege H, Merle P, Ebert O, Habersetzer F, Blanc JF, Rosmorduc O, Lencioni R, Patt R, Leen AM, Foerster F, Homerin M, Stojkowitz N, Lusky M, Limacher JM, Hennequi M, Gaspar N, McFadden B, De Silva N, Shen D, Pelusio A, Kirn DH, Breitbach CJ, Burke JM. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE). Oncoimmunology 2019;8:1615817. [PMID: 31413923 DOI: 10.1080/2162402X.2019.1615817] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 10.3] [Reference Citation Analysis]
278 Dyhl-Polk A, Mikkelsen MK, Ladekarl M, Nielsen DL. Clinical Trials of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. J Clin Med 2021;10:2662. [PMID: 34208788 DOI: 10.3390/jcm10122662] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep 2021;3:100215. [PMID: 33392490 DOI: 10.1016/j.jhepr.2020.100215] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
280 Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019;9:588-596. [PMID: 31695249 DOI: 10.1016/j.jceh.2019.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
281 Une N, Takano-Kasuya M, Kitamura N, Ohta M, Inose T, Kato C, Nishimura R, Tada H, Miyagi S, Ishida T, Unno M, Kamei T, Gonda K. The anti-angiogenic agent lenvatinib induces tumor vessel normalization and enhances radiosensitivity in hepatocellular tumors. Med Oncol 2021;38:60. [PMID: 33881631 DOI: 10.1007/s12032-021-01503-z] [Reference Citation Analysis]
282 Cacicedo ML, Medina-Montano C, Kaps L, Kappel C, Gehring S, Bros M. Role of Liver-Mediated Tolerance in Nanoparticle-Based Tumor Therapy. Cells 2020;9:E1985. [PMID: 32872352 DOI: 10.3390/cells9091985] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
283 Masch WR, Kampalath R, Parikh N, Shampain KA, Aslam A, Chernyak V. Imaging of treatment response during systemic therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2021;46:3625-33. [PMID: 33950406 DOI: 10.1007/s00261-021-03100-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
284 Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open 2021;6:100330. [PMID: 34847382 DOI: 10.1016/j.esmoop.2021.100330] [Reference Citation Analysis]
285 Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Ther Adv Med Oncol 2021;13:17588359211031141. [PMID: 34377156 DOI: 10.1177/17588359211031141] [Reference Citation Analysis]
286 Spahn S, Roessler D, Pompilia R, Gabernet G, Gladstone BP, Horger M, Biskup S, Feldhahn M, Nahnsen S, Hilke FJ, Scheiner B, Dufour JF, De Toni EN, Pinter M, Malek NP, Bitzer M. Clinical and Genetic Tumor Characteristics of Responding and Non-Responding Patients to PD-1 Inhibition in Hepatocellular Carcinoma. Cancers (Basel). 2020;12. [PMID: 33353145 DOI: 10.3390/cancers12123830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
287 Wong KM, King GG, Harris WP. The Treatment Landscape of Advanced Hepatocellular Carcinoma. Curr Oncol Rep. [DOI: 10.1007/s11912-022-01247-7] [Reference Citation Analysis]
288 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Kelley RK, Meyer T, Rimassa L, Merle P, Park JW, Yau T, Chan SL, Blanc JF, Tam VC, Tran A, Dadduzio V, Markby DW, Kaldate R, Cheng AL, El-Khoueiry AB, Abou-Alfa GK. Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res 2020;26:4795-804. [PMID: 32636319 DOI: 10.1158/1078-0432.CCR-19-3884] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
290 Tomonari T, Sato Y, Tanaka H, Tanaka T, Taniguchi T, Sogabe M, Okamoto K, Miyamoto H, Muguruma N, Takayama T. Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma. JGH Open 2020;4:1135-9. [PMID: 33319048 DOI: 10.1002/jgh3.12408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
291 Mossenta M, Busato D, Dal Bo M, Toffoli G. Glucose Metabolism and Oxidative Stress in Hepatocellular Carcinoma: Role and Possible Implications in Novel Therapeutic Strategies. Cancers (Basel) 2020;12:E1668. [PMID: 32585931 DOI: 10.3390/cancers12061668] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
292 Fung AS, Tam VC, Meyers DE, Sim HW, Knox JJ, Zaborska V, Davies J, Ko YJ, Batuyong E, Samawi H, Cheung WY, Lee-Ying R. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab. Cancer Med 2020;9:4640-7. [PMID: 32378799 DOI: 10.1002/cam4.3116] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
293 Piñero F, Dirchwolf M, Pessôa MG. Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment. Cells 2020;9:E1370. [PMID: 32492896 DOI: 10.3390/cells9061370] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
294 Kaseb AO, Kappadath SC, Lee SS, Raghav KP, Mohamed YI, Xiao L, Morris JS, Ohaji C, Avritscher R, Odisio BC, Kuban J, Abdelsalam ME, Chasen B, Elsayes KM, Elbanan M, Wolff RA, Yao JC, Mahvash A. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1129-45. [PMID: 34527608 DOI: 10.2147/JHC.S318865] [Reference Citation Analysis]
295 Liu T, Shen Y, Cheng A. Immune checkpoint inhibitors for hepatocellular carcinoma – A game changer in treatment landscape. Journal of the Formosan Medical Association 2022. [DOI: 10.1016/j.jfma.2022.03.017] [Reference Citation Analysis]
296 Chang Y, Jeong SW, Young Jang J, Jae Kim Y. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E8165. [PMID: 33142892 DOI: 10.3390/ijms21218165] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
297 Korhan P, Tercan Avcı S, Yılmaz Y, Öztemur Islakoğlu Y, Atabey N. Role of Biobanks for Cancer Research and Precision Medicine in Hepatocellular Carcinoma. J Gastrointest Cancer 2021. [PMID: 34807351 DOI: 10.1007/s12029-021-00759-y] [Reference Citation Analysis]
298 Zhu M, Jin Z, Hubbard JM. Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. Cancers (Basel) 2021;13:651. [PMID: 33561950 DOI: 10.3390/cancers13040651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
299 Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA. New landscapes and horizons in hepatocellular carcinoma therapy. Aging (Albany NY) 2020;12:3053-94. [PMID: 32018226 DOI: 10.18632/aging.102777] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
300 Guardascione M, Toffoli G. Immune Checkpoint Inhibitors as Monotherapy or Within a Combinatorial Strategy in Advanced Hepatocellular Carcinoma. Int J Mol Sci 2020;21:E6302. [PMID: 32878115 DOI: 10.3390/ijms21176302] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
301 Rubinstein MM, Brown KA, Iyengar NM. Targeting obesity-related dysfunction in hormonally driven cancers. Br J Cancer 2021;125:495-509. [PMID: 33911195 DOI: 10.1038/s41416-021-01393-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
302 Kudo M. Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma. Liver Cancer 2020;9:232-44. [PMID: 32884915 DOI: 10.1159/000507889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
303 Greten TF, Abou-Alfa GK, Cheng AL, Duffy AG, El-Khoueiry AB, Finn RS, Galle PR, Goyal L, He AR, Kaseb AO, Kelley RK, Lencioni R, Lujambio A, Mabry Hrones D, Pinato DJ, Sangro B, Troisi RI, Wilson Woods A, Yau T, Zhu AX, Melero I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. J Immunother Cancer 2021;9:e002794. [PMID: 34518290 DOI: 10.1136/jitc-2021-002794] [Reference Citation Analysis]
304 Terashima T, Yamashita T, Takata N, Takeda Y, Kido H, Iida N, Kitahara M, Shimakami T, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. Hepatol Res 2021;51:190-200. [PMID: 33197087 DOI: 10.1111/hepr.13588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
305 Schulte LA, López-Gil JC, Sainz B Jr, Hermann PC. The Cancer Stem Cell in Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E684. [PMID: 32183251 DOI: 10.3390/cancers12030684] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
306 Huang J, Guo Y, Huang W, Hong X, Quan Y, Lin L, Zhou J, Liang L, Zhang Y, Zhou J, Cai M, Zhu K. Regorafenib Combined with PD-1 Blockade Immunotherapy versus Regorafenib as Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Multicenter Retrospective Study. JHC 2022;Volume 9:157-70. [DOI: 10.2147/jhc.s353956] [Reference Citation Analysis]
307 Losurdo G, Gravina AG, Maroni L, Gabrieletto EM, Ianiro G, Ferrarese A; Young Investigator group of SIGE, the Italian Society of Gastroenterology. Future challenges in gastroenterology and hepatology, between innovations and unmet needs: A SIGE Young Editorial Board's perspective. Dig Liver Dis 2021:S1590-8658(21)00455-2. [PMID: 34509394 DOI: 10.1016/j.dld.2021.08.008] [Reference Citation Analysis]
308 Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
309 Kudo M. Gd-EOB-DTPA-MRI Could Predict WNT/β-Catenin Mutation and Resistance to Immune Checkpoint Inhibitor Therapy in Hepatocellular Carcinoma. Liver Cancer 2020;9:479-90. [PMID: 33083276 DOI: 10.1159/000509554] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
310 Eso Y. Targeting Angiogenesis for Advanced Hepatocellular Carcinoma. Intern Med 2021;60:321-2. [PMID: 32963171 DOI: 10.2169/internalmedicine.5923-20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 O'Brien B. Developments in Hepatocellular Cancer Treatment. J Adv Pract Oncol 2021;12:310-4. [PMID: 34084581 DOI: 10.6004/jadpro.2021.12.3.19] [Reference Citation Analysis]
312 Xu S, Lai R, Zhao Q, Zhao P, Zhao R, Guo Z. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors. Front Immunol 2021;12:794099. [PMID: 34950153 DOI: 10.3389/fimmu.2021.794099] [Reference Citation Analysis]
313 Bao MH, Wong CC. Hypoxia, Metabolic Reprogramming, and Drug Resistance in Liver Cancer. Cells 2021;10:1715. [PMID: 34359884 DOI: 10.3390/cells10071715] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Foerster F, Gairing SJ, Ilyas SI, Galle PR. Emerging immunotherapy for HCC: A guide for hepatologists. Hepatology 2022;75:1604-26. [PMID: 35253934 DOI: 10.1002/hep.32447] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
315 Altayar O, Shah R, Chang CY, Falck-Ytter Y, Muir AJ. AGA Technical Review on Systemic Therapies for Hepatocellular Carcinoma. Gastroenterology 2022;162:937-51. [PMID: 35210015 DOI: 10.1053/j.gastro.2021.12.275] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
316 Nishida N, Kudo M. Immune Phenotype and Immune Checkpoint Inhibitors for the Treatment of Human Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1274. [PMID: 32443599 DOI: 10.3390/cancers12051274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
317 Yen CJ, Kudo M, Lim HY, Hsu CH, Vogel A, Brandi G, Cheng R, Nitu IS, Abada P, Hsu Y, Zhu AX, Kang YK. Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies. Liver Cancer 2020;9:440-54. [PMID: 32999870 DOI: 10.1159/000506946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
318 Hou GM, Liu HL, Wu H, Zeng Y. Prediction of Prognosis for cHCC-CC Patients After Surgery: Comparison of Tumor Marker Score Based on AFP, CEA, CA19-9, and Other Clinical Stages. Ann Surg Oncol 2021. [PMID: 33900502 DOI: 10.1245/s10434-021-09949-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
319 Mangia A, Bellini D, Cillo U, Laghi A, Pelle G, Valori VM, Caturelli E. Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence. BMC Gastroenterol 2020;20:251. [PMID: 32746786 DOI: 10.1186/s12876-020-01391-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
320 Gholam PM, Iyer R, Johnson MS. Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence. Cancers (Basel) 2019;11:E873. [PMID: 31234476 DOI: 10.3390/cancers11060873] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
321 Kosaka Y, Kimura T, Kawaoka T, Ogawa Y, Amioka K, Naruto K, Yoshikawa Y, Kikukawa C, Suehiro Y, Yamaoka K, Ando Y, Uchikawa S, Morio K, Nakahara T, Murakami E, Takahashi S, Tsuge M, Hiramatsu A, Imamura M, Chosa K, Awai K, Nagata Y, Chayama K, Aikata H. Hepatic Arterial Infusion Chemotherapy Combined with Radiation Therapy for Advanced Hepatocellular Carcinoma with Tumor Thrombosis of the Main Trunk or Bilobar of the Portal Vein. Liver Cancer 2021;10:151-60. [PMID: 33977091 DOI: 10.1159/000513706] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
322 Sekiguchi S, Tsuchiya K, Yasui Y, Inada K, Kirino S, Yamashita K, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Kurosaki M, Izumi N. Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy. Cancer Rep (Hoboken) 2022;:e1613. [PMID: 35302279 DOI: 10.1002/cnr2.1613] [Reference Citation Analysis]
323 Pérez LM, López SA, Fajes JH, Martín LC. Carcinoma hepatocelular. Medicine - Programa de Formación Médica Continuada Acreditado 2020;13:653-65. [DOI: 10.1016/j.med.2020.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
324 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
325 Nakatsuka T, Nakagawa H, Hayata Y, Wake T, Yamada T, Nishibatake Kinoshita M, Nakagomi R, Sato M, Minami T, Uchino K, Enooku K, Kudo Y, Tanaka Y, Kishikawa T, Otsuka M, Tateishi R, Koike K. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. J Gastroenterol 2021;56:456-69. [PMID: 33712873 DOI: 10.1007/s00535-021-01773-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
326 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
327 Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel) 2021;13:3248. [PMID: 34209646 DOI: 10.3390/cancers13133248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
328 Furukawa K, Nagano T, Tachihara M, Yamamoto M, Nishimura Y. Interaction between Immunotherapy and Antiangiogenic Therapy for Cancer. Molecules 2020;25:E3900. [PMID: 32859106 DOI: 10.3390/molecules25173900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
329 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
330 Lyu N, Kong Y, Li X, Mu L, Deng H, Chen H, He M, Lai J, Li J, Tang H, Lin Y, Zhao M. Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study. Front Oncol 2020;10:580241. [PMID: 33163408 DOI: 10.3389/fonc.2020.580241] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
331 Vitale G, Gitto S, Campani C, Turco L, Baldan A, Marra F, Morelli MC. Biological therapies in patients with liver disease: are they really lifesavers? Expert Opin Biol Ther 2021;:1-18. [PMID: 34860629 DOI: 10.1080/14712598.2022.2013799] [Reference Citation Analysis]
332 Winograd P, Hou S, Court CM, Lee YT, Chen PJ, Zhu Y, Sadeghi S, Finn RS, Teng PC, Wang JJ, Zhang Z, Liu H, Busuttil RW, Tomlinson JS, Tseng HR, Agopian VG. Hepatocellular Carcinoma-Circulating Tumor Cells Expressing PD-L1 Are Prognostic and Potentially Associated With Response to Checkpoint Inhibitors. Hepatol Commun 2020;4:1527-40. [PMID: 33024921 DOI: 10.1002/hep4.1577] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
333 Arora SP, Liposits G, Caird S, Dunne RF, Moffat GT, Okonji D, Rodriquenz MG, Dua D, Dotan E. Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology. J Geriatr Oncol 2020;11:557-65. [PMID: 31704038 DOI: 10.1016/j.jgo.2019.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
334 Galicia-Moreno M, Silva-Gomez JA, Lucano-Landeros S, Santos A, Monroy-Ramirez HC, Armendariz-Borunda J. Liver Cancer: Therapeutic Challenges and the Importance of Experimental Models. Can J Gastroenterol Hepatol 2021;2021:8837811. [PMID: 33728291 DOI: 10.1155/2021/8837811] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
335 D'Avola D, Granito A, de la Torre-Aláez M, Piscaglia F. The importance of liver functional reserve in the non-surgical treatment of Hepatocellular Carcinoma. J Hepatol 2021:S0168-8278(21)02185-1. [PMID: 34793869 DOI: 10.1016/j.jhep.2021.11.013] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
336 Debaillon Vesque A, Decraecker M, Blanc JF. Profile of Cabozantinib for the Treatment of Hepatocellular Carcinoma: Patient Selection and Special Considerations. J Hepatocell Carcinoma 2020;7:91-9. [PMID: 32607316 DOI: 10.2147/JHC.S195570] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
337 Rajappa S, Rau KM, Dattatreya PS, Ramaswamy A, Fernandes P, Pruthi A, Cheng R, Lukanowski M, Huang YH. Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options? World J Hepatol 2022; 14(6): 1074-1086 [DOI: 10.4254/wjh.v14.i6.1074] [Reference Citation Analysis]
338 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
339 Yang F, Deng K, Zheng H, Liu Z, Zheng Y. Progress of targeted and immunotherapy for hepatocellular carcinoma and the application of next-generation sequencing. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100677] [Reference Citation Analysis]
340 Hong YM, Yoon KT, Cho M. Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma. BMC Cancer 2021;21:569. [PMID: 34006248 DOI: 10.1186/s12885-021-08124-9] [Reference Citation Analysis]
341 Carrier P, Debette-Gratien M, Jacques J, Loustaud-Ratti V. Cirrhotic patients and older people. World J Hepatol 2019; 11(9): 663-677 [PMID: 31598192 DOI: 10.4254/wjh.v11.i9.663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
342 Hayakawa Y, Tsuchiya K, Kurosaki M, Yasui Y, Kaneko S, Tanaka Y, Ishido S, Inada K, Kirino S, Yamashita K, Nobusawa T, Matsumoto H, Kakegawa T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Okamoto R, Izumi N. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. Invest New Drugs 2021. [PMID: 34586531 DOI: 10.1007/s10637-021-01185-4] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
343 Cammarota A, D'Alessio A, Pressiani T, Rimassa L, Personeni N. Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs Aging 2021;38:579-91. [PMID: 34152589 DOI: 10.1007/s40266-021-00871-5] [Reference Citation Analysis]
344 Chung SW, Park MK, Cho YY, Park Y, Lee CH, Oh H, Jang H, Kim MA, Kim SW, Nam JY, Lee YB, Cho EJ, Yu SJ, Kim HC, Kim YJ, Chung JW, Yoon JH, Lee JH. Effectiveness of Transarterial Chemoembolization-First Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J Hepatocell Carcinoma 2021;8:587-98. [PMID: 34164351 DOI: 10.2147/JHC.S294440] [Reference Citation Analysis]
345 Shigeta K, Datta M, Hato T, Kitahara S, Chen IX, Matsui A, Kikuchi H, Mamessier E, Aoki S, Ramjiawan RR, Ochiai H, Bardeesy N, Huang P, Cobbold M, Zhu AX, Jain RK, Duda DG. Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma. Hepatology 2020;71:1247-61. [PMID: 31378984 DOI: 10.1002/hep.30889] [Cited by in Crossref: 108] [Cited by in F6Publishing: 101] [Article Influence: 54.0] [Reference Citation Analysis]
346 Ziogas IA, Evangeliou AP, Giannis D, Hayat MH, Mylonas KS, Tohme S, Geller DA, Elias N, Goyal L, Tsoulfas G. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients. Oncologist 2021;26:e1036-49. [PMID: 33314549 DOI: 10.1002/onco.13638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
347 Rimassa L. Novel Therapies for Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E3049. [PMID: 33092015 DOI: 10.3390/cancers12103049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
348 Rapposelli IG, De Matteis S, Lanuti P, Valgiusti M, Bartolini G, Ulivi P, Marisi G, Pedica F, Burgio V, Frassineti GL, Cascinu S, Casadei-Gardini A. Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. Cancers (Basel) 2021;13:E213. [PMID: 33430142 DOI: 10.3390/cancers13020213] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
349 Moon H, Ro SW. MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3026. [PMID: 34204242 DOI: 10.3390/cancers13123026] [Reference Citation Analysis]
350 Sun Y, Zhou A, Zhang W, Jiang Z, Chen B, Zhao J, Li Z, Wang L, Bi X, Zhao H, Liu K. Anlotinib in the treatment of advanced hepatocellular carcinoma: an open-label phase II study (ALTER-0802 study). Hepatol Int 2021;15:621-9. [PMID: 33826043 DOI: 10.1007/s12072-021-10171-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Nomura A, Terashima T, Mizukoshi E, Kitahara M, Murayama T, Kaneko S. Protocol For An Adjuvant Alpha-Fetoprotein-Derived Peptide After Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: Safety Study. JMIR Res Protoc 2020;9:e17082. [PMID: 32039814 DOI: 10.2196/17082] [Reference Citation Analysis]
352 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
353 Renne SL, Sarcognato S, Sacchi D, Guido M, Roncalli M, Terracciano L, Di Tommaso L. Hepatocellular carcinoma: a clinical and pathological overview. Pathologica 2021;113:203-17. [PMID: 34294938 DOI: 10.32074/1591-951X-295] [Reference Citation Analysis]
354 Koulouris A, Tsagkaris C, Spyrou V, Pappa E, Troullinou A, Nikolaou M. Hepatocellular Carcinoma: An Overview of the Changing Landscape of Treatment Options. J Hepatocell Carcinoma 2021;8:387-401. [PMID: 34012929 DOI: 10.2147/JHC.S300182] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
355 Zhang H, Zhang W, Jiang L, Chen Y. Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 2022;10:3. [PMID: 35000616 DOI: 10.1186/s40364-021-00350-4] [Reference Citation Analysis]
356 Laface C, Laforgia M, Molinari P, Ugenti I, Gadaleta CD, Porta C, Ranieri G. Hepatic Arterial Infusion of Chemotherapy for Advanced Hepatobiliary Cancers: State of the Art. Cancers (Basel) 2021;13:3091. [PMID: 34205656 DOI: 10.3390/cancers13123091] [Reference Citation Analysis]
357 Cheng TY, Lee PC, Chen YT, Chao Y, Hou MC, Huang YH. Pre-sarcopenia determines post-progression outcomes in advanced hepatocellular carcinoma after sorafenib failure. Sci Rep 2020;10:18375. [PMID: 33110117 DOI: 10.1038/s41598-020-75198-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
358 Piñero F, Silva M, Iavarone M. Sequencing of systemic treatment for hepatocellular carcinoma: Second line competitors. World J Gastroenterol 2020; 26(16): 1888-1900 [PMID: 32390700 DOI: 10.3748/wjg.v26.i16.1888] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
359 Roviello G, Sohbani N, Petrioli R, Rodriquenz MG. Ramucirumab as a second line therapy for advanced HCC: a significant achievement or a wasted opportunity for personalised therapy? Invest New Drugs 2019;37:1274-88. [PMID: 30879152 DOI: 10.1007/s10637-019-00760-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
360 Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncol 2020;6:e204564. [PMID: 33001135 DOI: 10.1001/jamaoncol.2020.4564] [Cited by in Crossref: 211] [Cited by in F6Publishing: 189] [Article Influence: 105.5] [Reference Citation Analysis]
361 Pathak S, Sonbol MB. Second-Line Treatment Options for Hepatocellular Carcinoma: Current Landscape and Future Direction. J Hepatocell Carcinoma 2021;8:1147-58. [PMID: 34584898 DOI: 10.2147/JHC.S268314] [Reference Citation Analysis]
362 Moawad AW, Szklaruk J, Lall C, Blair KJ, Kaseb AO, Kamath A, Rohren SA, Elsayes KM. Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. J Hepatocell Carcinoma 2020;7:77-89. [PMID: 32426302 DOI: 10.2147/JHC.S224471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
363 Piñero F, Thompson M, Marín JI, Silva M. Lenvatinib as first-line therapy for recurrent hepatocellular carcinoma after liver transplantation: Is the current evidence applicable to these patients? World J Transplant 2020; 10(11): 297-306 [PMID: 33312891 DOI: 10.5500/wjt.v10.i11.297] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
364 Lin JC, Liu TP, Andriani V, Athoillah M, Wang CY, Yang PM. Bioinformatics Analysis Identifies Precision Treatment with Paclitaxel for Hepatocellular Carcinoma Patients Harboring Mutant TP53 or Wild-Type CTNNB1 Gene. J Pers Med 2021;11:1199. [PMID: 34834551 DOI: 10.3390/jpm11111199] [Reference Citation Analysis]
365 Liu CM, Huang BS, Yen YH, Wang YM, Huang EY, Hsu HC, Huang TT, Yang YH, Cheng JY. Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis. J Hepatocell Carcinoma 2021;8:963-73. [PMID: 34434903 DOI: 10.2147/JHC.S323302] [Reference Citation Analysis]
366 Oya M, Kaneko S, Imai T, Tsujino T, Sunaya T, Okayama Y. Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer Chemother Pharmacol 2022. [PMID: 35445315 DOI: 10.1007/s00280-022-04428-0] [Reference Citation Analysis]
367 Zhang H, Spencer K, Burley SK, Zheng XFS. Toward improving androgen receptor-targeted therapies in male-dominant hepatocellular carcinoma. Drug Discov Today 2021;26:1539-46. [PMID: 33561464 DOI: 10.1016/j.drudis.2021.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
368 Zhang Y, Lu L, He Z, Xu Z, Xiang Z, Nie R, Lin W, Chen W, Zhou J, Yin Y, Xie J, Zhang Y, Zheng X, Zhu T, Cai X, Li P, Chao X, Cai M. C-Reactive Protein Levels Predict Responses to PD-1 Inhibitors in Hepatocellular Carcinoma Patients. Front Immunol 2022;13:808101. [DOI: 10.3389/fimmu.2022.808101] [Reference Citation Analysis]
369 Ao J, Chiba T, Kanzaki H, Kanayama K, Shibata S, Kurosugi A, Iwanaga T, Kan M, Sakuma T, Qiang N, Ma Y, Kojima R, Kusakabe Y, Nakamura M, Kobayashi K, Kiyono S, Kanogawa N, Saito T, Nakagawa R, Kondo T, Ogasawara S, Suzuki E, Nakamoto S, Muroyama R, Tawada A, Kato J, Kanda T, Maruyama H, Kato N. Serum Angiopoietin 2 acts as a diagnostic and prognostic biomarker in hepatocellular carcinoma. J Cancer 2021;12:2694-701. [PMID: 33854629 DOI: 10.7150/jca.56436] [Reference Citation Analysis]
370 Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther 2020;5:146. [PMID: 32782275 DOI: 10.1038/s41392-020-00264-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 28] [Article Influence: 11.5] [Reference Citation Analysis]
371 Ronnebaum S, Aly A, Patel D, Benavente F, Rueda JD. Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma. Hepat Oncol 2022;9:HEP41. [PMID: 34765109 DOI: 10.2217/hep-2021-0003] [Reference Citation Analysis]
372 Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, Liu X. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency. Adv Sci (Weinh) 2022;9:e2105631. [PMID: 35142445 DOI: 10.1002/advs.202105631] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
373 Kamachi N, Shimose S, Hirota K, Koya S, Iwamoto H, Niizeki T, Shirono T, Nakano M, Hashida R, Kawaguchi T, Matuse H, Noguchi K, Koga H, Torimura T. Prevalence and profiles of ramucirumab-associated severe ascites in patients with hepatocellular carcinoma. Mol Clin Oncol 2021;14:79. [PMID: 33758660 DOI: 10.3892/mco.2021.2241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
374 Wang H, Rao B, Lou J, Li J, Liu Z, Li A, Cui G, Ren Z, Yu Z. The Function of the HGF/c-Met Axis in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:55. [PMID: 32117981 DOI: 10.3389/fcell.2020.00055] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
375 Kudo M. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials. Liver Cancer. 2019;8:221-238. [PMID: 31602367 DOI: 10.1159/000501501] [Cited by in Crossref: 16] [Cited by in F6Publishing: 25] [Article Influence: 5.3] [Reference Citation Analysis]
376 Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019;79:4326-4330. [PMID: 31481419 DOI: 10.1158/0008-5472.can-19-0803] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
377 Liang L, Wang MD, Zhang YM, Zhang WG, Zhang CW, Lau WY, Shen F, Pawlik TM, Huang DS, Yang T. Association of Postoperative Biomarker Response with Recurrence and Survival in Patients with Hepatocellular Carcinoma and High Alpha-Fetoprotein Expressions (>400 ng/ml). J Hepatocell Carcinoma 2021;8:103-18. [PMID: 33748017 DOI: 10.2147/JHC.S289840] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
378 Khan AR, Wei X, Xu X. Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides. J Hepatocell Carcinoma 2021;8:1089-115. [PMID: 34522691 DOI: 10.2147/JHC.S318070] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
379 Tella SH, Kommalapati A, Mahipal A, Jin Z. First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. Biomedicines 2022;10:1304. [DOI: 10.3390/biomedicines10061304] [Reference Citation Analysis]
380 El Dika I, Makki I, Abou-Alfa GK. Hepatocellular carcinoma, novel therapies on the horizon. Chin Clin Oncol 2021;10:12. [PMID: 32527116 DOI: 10.21037/cco-20-113] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
381 Su GL, Altayar O, O'Shea R, Shah R, Estfan B, Wenzell C, Sultan S, Falck-Ytter Y. AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma. Gastroenterology 2022;162:920-34. [PMID: 35210014 DOI: 10.1053/j.gastro.2021.12.276] [Reference Citation Analysis]
382 Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HL. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov 2021;11:308-25. [PMID: 33234578 DOI: 10.1158/2159-8290.CD-20-1408] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
383 Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
384 Aliya S, Lee H, Alhammadi M, Umapathi R, Huh YS. An Overview on Single-Cell Technology for Hepatocellular Carcinoma Diagnosis. Int J Mol Sci 2022;23:1402. [PMID: 35163329 DOI: 10.3390/ijms23031402] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
385 Shek D, Read SA, Nagrial A, Carlino MS, Gao B, George J, Ahlenstiel G. Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. Oncologist 2021;26:e1216-25. [PMID: 33818870 DOI: 10.1002/onco.13776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
386 Raja A, Park I, Haq F, Ahn SM. FGF19-FGFR4 Signaling in Hepatocellular Carcinoma. Cells. 2019;8:pii: E536. [PMID: 31167419 DOI: 10.3390/cells8060536] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 13.7] [Reference Citation Analysis]
387 Orsi G, Tovoli F, Dadduzio V, Vivaldi C, Brunetti O, Ielasi L, Conti F, Rovesti G, Gramantieri L, Rizzato MD, Pecora I, Argentiero A, Teglia F, Lonardi S, Salani F, Granito A, Zagonel V, Marisi G, Cabibbo G, Foschi FG, Benevento F, Cucchetti A, Piscaglia F, Cascinu S, Scartozzi M, Casadei-Gardini A. Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. Target Oncol 2020;15:773-85. [PMID: 33044683 DOI: 10.1007/s11523-020-00757-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
388 Tsuchiya K, Kurosaki M, Sakamoto A, Marusawa H, Kojima Y, Hasebe C, Arai H, Joko K, Kondo M, Tsuji K, Sohda T, Kimura H, Ogawa C, Uchida Y, Wada S, Kobashi H, Furuta K, Shigeno M, Kusakabe A, Akahane T, Narita R, Yoshida H, Mitsuda A, Ide Y, Matsushita T, Izumi N, On Behalf Of Japanese Red Cross Liver Study Group. The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers (Basel) 2021;13:2608. [PMID: 34073396 DOI: 10.3390/cancers13112608] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
389 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
390 Obi S, Sato T, Sato S. Immune checkpoint inhibitor in liver cancer-unique regional differences. Ann Transl Med 2020;8:1336. [PMID: 33313081 DOI: 10.21037/atm-20-3378] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
391 Dai L, Cai X, Mugaanyi J, Liu Y, Mao S, Lu C, Lu C. Therapeutic effectiveness and safety of sintilimab-dominated triple therapy in unresectable hepatocellular carcinoma. Sci Rep 2021;11:19711. [PMID: 34611195 DOI: 10.1038/s41598-021-98937-2] [Reference Citation Analysis]
392 Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. [PMID: 31439937 DOI: 10.1038/s41575-019-0186-y] [Cited by in Crossref: 690] [Cited by in F6Publishing: 718] [Article Influence: 230.0] [Reference Citation Analysis]
393 Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 2022:S0168-8278(22)00031-9. [PMID: 35143898 DOI: 10.1016/j.jhep.2022.01.018] [Reference Citation Analysis]
394 Kamachi N, Nakano M, Okamura S, Niizeki T, Iwamoto H, Shimose S, Shirono T, Noda Y, Kuromatsu R, Koga H, Torimura T. Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound. Cancer Rep (Hoboken) 2021;:e1471. [PMID: 34105904 DOI: 10.1002/cnr2.1471] [Reference Citation Analysis]
395 Narahara S, Watanabe T, Nagaoka K, Fujimoto N, Furuta Y, Tanaka K, Tokunaga T, Kawasaki T, Yoshimaru Y, Setoyama H, Oniki K, Saruwatari J, Tateyama M, Naoe H, Tanaka M, Tanaka Y, Sasaki Y. Clusterin and Related Scoring Index as Potential Early Predictors of Response to Sorafenib in Hepatocellular Carcinoma. Hepatol Commun 2021. [PMID: 34837478 DOI: 10.1002/hep4.1872] [Reference Citation Analysis]
396 Sharma R, Pillai A, Marron TU, Fessas P, Saeed A, Jun T, Dharmapuri S, Szafron D, Naqash AR, Gampa A, Wang Y, Khan U, Muzaffar M, Lee CJ, Lee PC, Bulumulle A, Paul S, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Kaseb A, Huang YH, Ang C, Kudo M, Nishida N, Personeni N, Rimassa L, Pinato DJ. Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC. Hepatol Commun 2022. [PMID: 35481940 DOI: 10.1002/hep4.1927] [Reference Citation Analysis]
397 Yacoub JH, Mauro D, Moon A, He AR, Bashir MR, Hsu CC, Fishbein TM, Burke LMB. Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation. Part two: noncurative intention. Abdom Radiol (NY) 2021;46:3540-8. [PMID: 33864107 DOI: 10.1007/s00261-021-03074-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
398 von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A. Liquid biopsy in the clinical management of hepatocellular carcinoma. Gut 2020;69:2025-34. [PMID: 32883873 DOI: 10.1136/gutjnl-2019-320282] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 16.0] [Reference Citation Analysis]
399 Rimassa L, Wörns MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma. Liver Int 2020;40:1800-11. [PMID: 32432830 DOI: 10.1111/liv.14533] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
400 Nam Y, Shin I, Kim Y, Ryu S, Kim N, Ju E, Sim T. Anti-cancer effects of 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives on hepatocellular carcinoma harboring FGFR4 activation. Neoplasia 2022;24:34-49. [PMID: 34864570 DOI: 10.1016/j.neo.2021.11.011] [Reference Citation Analysis]
401 Tomonari T, Sato Y, Tani J, Hirose A, Ogawa C, Morishita A, Tanaka H, Tanaka T, Taniguchi T, Okamoto K, Sogabe M, Miyamoto H, Muguruma N, Uchida K, Masaki T, Takayama T. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis. Hepatol Res 2021;51:472-81. [PMID: 33238074 DOI: 10.1111/hepr.13597] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
402 Duda DG, Dima SO, Cucu D, Sorop A, Klein S, Ancukiewicz M, Kitahara S, Iacob S, Bacalbasa N, Tomescu D, Herlea V, Tanase C, Croitoru A, Popescu I. Potential Circulating Biomarkers of Recurrence after Hepatic Resection or Liver Transplantation in Hepatocellular Carcinoma Patients. Cancers (Basel) 2020;12:E1275. [PMID: 32443546 DOI: 10.3390/cancers12051275] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
403 D'Alessio A, Prete MG, Cammarota A, Personeni N, Rimassa L. The Role of Cabozantinib as a Therapeutic Option for Hepatocellular Carcinoma: Current Landscape and Future Challenges. J Hepatocell Carcinoma 2021;8:177-91. [PMID: 33824862 DOI: 10.2147/JHC.S268310] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2021;18:525-43. [PMID: 33850328 DOI: 10.1038/s41575-021-00438-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 20] [Article Influence: 14.0] [Reference Citation Analysis]
405 Piñero F, da Fonseca LG. Trial eligibility in advanced hepatocellular carcinoma: Does it support clinical practice in underrepresented subgroups? World J Gastroenterol 2021; 27(24): 3429-3439 [PMID: 34239261 DOI: 10.3748/wjg.v27.i24.3429] [Reference Citation Analysis]
406 Cui H, Dai G, Guan J. Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World. Onco Targets Ther 2020;13:143-9. [PMID: 32021262 DOI: 10.2147/OTT.S234868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
407 Wege H, Li J, Ittrich H. Treatment Lines in Hepatocellular Carcinoma. Visc Med 2019;35:266-72. [PMID: 31602390 DOI: 10.1159/000501749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
408 Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. Hepatobiliary Surg Nutr. 2020;9:452-463. [PMID: 32832496 DOI: 10.21037/hbsn-20-480] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
409 Cui TM, Liu Y, Wang JB, Liu LX. Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma. Onco Targets Ther 2020;13:11725-40. [PMID: 33235462 DOI: 10.2147/OTT.S279858] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
410 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
411 Mehta N. Hepatocellular Carcinoma-How to Determine Therapeutic Options. Hepatol Commun 2020;4:342-54. [PMID: 32140653 DOI: 10.1002/hep4.1481] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
412 Ahn JC, Teng PC, Chen PJ, Posadas E, Tseng HR, Lu SC, Yang JD. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology 2021;73:422-36. [PMID: 32017145 DOI: 10.1002/hep.31165] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 58.0] [Reference Citation Analysis]
413 Shigeta K, Matsui A, Kikuchi H, Klein S, Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, Hato T, Ramjiawan RR, Staiculescu D, Zopf D, Fiebig L, Hobbs GS, Quaas A, Dima S, Popescu I, Huang P, Munn LL, Cobbold M, Goyal L, Zhu AX, Jain RK, Duda DG. Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma. J Immunother Cancer 2020;8:e001435. [PMID: 33234602 DOI: 10.1136/jitc-2020-001435] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
414 Ma YS, Liu JB, Wu TM, Fu D. New Therapeutic Options for Advanced Hepatocellular Carcinoma. Cancer Control 2020;27:1073274820945975. [PMID: 32799550 DOI: 10.1177/1073274820945975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
415 Hu B, Xu Y, Li YC, Huang JF, Cheng JW, Guo W, Yin Y, Gao Y, Wang PX, Wu SY, Zhou J, Fan J, Yang XR. CD13 promotes hepatocellular carcinogenesis and sorafenib resistance by activating HDAC5-LSD1-NF-κB oncogenic signaling. Clin Transl Med 2020;10:e233. [PMID: 33377659 DOI: 10.1002/ctm2.233] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
416 Xie D, Sun Q, Wang X, Zhou J, Fan J, Ren Z, Gao Q. Immune checkpoint inhibitor plus tyrosine kinase inhibitor for unresectable hepatocellular carcinoma in the real world. Ann Transl Med 2021;9:652. [PMID: 33987350 DOI: 10.21037/atm-20-7037] [Reference Citation Analysis]
417 Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, Ridruejo E, Romero G, Ameigeiras B, D’Amico C, Gaite L, Bermúdez C, Reggiardo V, Colombato L, Gadano A, Silva M. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019; 25(27): 3607-3618 [PMID: 31367160 DOI: 10.3748/wjg.v25.i27.3607] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
418 Cersosimo RJ. Systemic targeted and immunotherapy for advanced hepatocellular carcinoma. Am J Health Syst Pharm 2021;78:187-202. [PMID: 33211092 DOI: 10.1093/ajhp/zxaa365] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
419 Gallage S, García-beccaria M, Szydlowska M, Rahbari M, Mohr R, Tacke F, Heikenwalder M. The therapeutic landscape of hepatocellular carcinoma. Med 2021;2:505-52. [DOI: 10.1016/j.medj.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
420 Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Front Oncol 2021;11:635731. [PMID: 34631513 DOI: 10.3389/fonc.2021.635731] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
421 Kelley RK, Ryoo BY, Merle P, Park JW, Bolondi L, Chan SL, Lim HY, Baron AD, Parnis F, Knox J, Cattan S, Yau T, Lougheed JC, Milwee S, El-Khoueiry AB, Cheng AL, Meyer T, Abou-Alfa GK. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. ESMO Open 2020;5:e000714. [PMID: 32847838 DOI: 10.1136/esmoopen-2020-000714] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
422 Cabibbo G, Celsa C, Enea M, Battaglia S, Rizzo GEM, Busacca A, Matranga D, Attanasio M, Reig M, Craxì A, Cammà C. Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma. Cancers (Basel) 2020;13:E90. [PMID: 33396833 DOI: 10.3390/cancers13010090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
423 Yao J, Zhu X, Wu Z, Wei Q, Cai Y, Zheng Y, Hu X, Hu H, Zhang X, Pan H, Zhong X, Han W. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Med 2022. [PMID: 35403359 DOI: 10.1002/cam4.4747] [Reference Citation Analysis]
424 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
425 Wang X, Gupta P, Jramne Y, Danilenko M, Liu D, Studzinski GP. Carnosic acid increases sorafenib-induced inhibition of ERK1/2 and STAT3 signaling which contributes to reduced cell proliferation and survival of hepatocellular carcinoma cells. Oncotarget 2020;11:3129-43. [PMID: 32913557 DOI: 10.18632/oncotarget.27687] [Reference Citation Analysis]
426 Maravelia P, Silva DN, Rovesti G, Chrobok M, Stål P, Lu YC, Pasetto A. Liquid Biopsy in Hepatocellular Carcinoma: Opportunities and Challenges for Immunotherapy. Cancers (Basel) 2021;13:4334. [PMID: 34503144 DOI: 10.3390/cancers13174334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
427 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
428 Hasan I, Loho IM, Setiawan PB, Djumhana A, Purnomo HD, Siregar L, Gani RA, Sulaiman AS, Lesmana CRA. Indonesian consensus on systemic therapies for hepatocellular carcinoma. Asia Pac J Clin Oncol 2022. [PMID: 35599455 DOI: 10.1111/ajco.13768] [Reference Citation Analysis]
429 Maestri M, Pallozzi M, Santopaolo F, Cerrito L, Pompili M, Gasbarrini A, Ponziani FR. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma. Expert Opinion on Investigational Drugs. [DOI: 10.1080/13543784.2022.2033208] [Reference Citation Analysis]
430 Ilyas FZ, Beane JD, Pawlik TM. The State of Immunotherapy in Hepatobiliary Cancers. Cells 2021;10:2096. [PMID: 34440865 DOI: 10.3390/cells10082096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Li E, Lin L, Chen CW, Ou DL. Mouse Models for Immunotherapy in Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E1800. [PMID: 31731753 DOI: 10.3390/cancers11111800] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
432 Matuszewska K, Pereira M, Petrik D, Lawler J, Petrik J. Normalizing Tumor Vasculature to Reduce Hypoxia, Enhance Perfusion, and Optimize Therapy Uptake. Cancers (Basel) 2021;13:4444. [PMID: 34503254 DOI: 10.3390/cancers13174444] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
433 Ozer M, George A, Goksu SY, George TJ, Sahin I. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Front Oncol 2021;11:801379. [PMID: 34956912 DOI: 10.3389/fonc.2021.801379] [Reference Citation Analysis]
434 Ko KL, Mak LY, Cheung KS, Yuen MF. Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Res 2020;9:F1000 Faculty Rev-620. [PMID: 32595940 DOI: 10.12688/f1000research.24543.1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
435 Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M. Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:615-28. [PMID: 34950184 DOI: 10.1159/000518048] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
436 Woo HY, Heo J. The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future. Ann Transl Med 2020;8:1617. [PMID: 33437816 DOI: 10.21037/atm-20-3387] [Reference Citation Analysis]
437 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Frizziero M, Mcnamara MG, Lamarca A, Pihlak R, Kurup R, Hubner RA. Current Translational and Clinical Challenges in Advanced Hepatocellular Carcinoma. CMC 2020;27:4789-805. [DOI: 10.2174/0929867327666200422143847] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
439 Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future. Genes Dis 2020;7:328-35. [PMID: 32884987 DOI: 10.1016/j.gendis.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
440 Elms D, Badami A, Dhanarajan A. Systemic Therapy in Metastatic Hepatocellular Carcinoma. Curr Gastroenterol Rep 2022. [PMID: 35416635 DOI: 10.1007/s11894-022-00842-9] [Reference Citation Analysis]
441 Chiang CL, Chan SK, Lee SF, Wong IO, Choi HC. Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma. JAMA Netw Open 2021;4:e2033761. [PMID: 33464318 DOI: 10.1001/jamanetworkopen.2020.33761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
442 Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J. Controversies in the management of hepatocellular carcinoma. JHEP Rep 2019;1:17-29. [PMID: 32039350 DOI: 10.1016/j.jhepr.2019.02.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
443 Liu ZL, Liu JH, Staiculescu D, Chen J. Combination of molecularly targeted therapies and immune checkpoint inhibitors in the new era of unresectable hepatocellular carcinoma treatment. Ther Adv Med Oncol 2021;13:17588359211018026. [PMID: 34104226 DOI: 10.1177/17588359211018026] [Reference Citation Analysis]
444 Yeh H, Chiang CC, Yen TH. Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges. World J Gastroenterol 2021; 27(26): 4104-4142 [PMID: 34326614 DOI: 10.3748/wjg.v27.i26.4104] [Reference Citation Analysis]
445 Dong MP, Enomoto M, Thuy LTT, Hai H, Hieu VN, Hoang DV, Iida-ueno A, Odagiri N, Amano-teranishi Y, Hagihara A, Fujii H, Uchida-kobayashi S, Tamori A, Kawada N. Clinical significance of circulating soluble immune checkpoint proteins in sorafenib-treated patients with advanced hepatocellular carcinoma. Sci Rep 2020;10. [DOI: 10.1038/s41598-020-60440-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 8.0] [Reference Citation Analysis]
446 Chen YY, Chen CL, Lin CC, Wang CC, Liu YW, Li WF, Chen YH. Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study. Cancers (Basel) 2021;13:4584. [PMID: 34572811 DOI: 10.3390/cancers13184584] [Reference Citation Analysis]
447 Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. JHEP Rep 2021;3:100304. [PMID: 34136776 DOI: 10.1016/j.jhepr.2021.100304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
448 Hayashi T, Shibata M, Oe S, Miyagawa K, Honma Y, Harada M. C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib. PLoS One 2020;15:e0244370. [PMID: 33351844 DOI: 10.1371/journal.pone.0244370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
449 Rajesh Y, Sarkar D. Molecular Mechanisms Regulating Obesity-Associated Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E1290. [PMID: 32443737 DOI: 10.3390/cancers12051290] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]